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CHAPTER 1: GENERAL INTRODUCTION AND LITERATURE REVIEW 
 
Dissertation Organization 
 
This dissertation follows the organizational format in which each chapter is an independent 
manuscript that has been accepted or submitted. These chapters follow the submission 
guidelines for the specific journals they were submitted. An overview and literature review, 
which comprises further details related to the dissertation, are included in Chapter 1. Chapter 2 
has been published in The Journal of Visualized Experiments. Chapter 3 has been published in 
Plos One. Chapter 4 has been submitted for publication to Frontiers in Immunology. Chapter 5 
encloses the general conclusions and future directions. 
 
Overview 
 
Mycobacterium bovis is the causative agent of tuberculosis in cattle. M. bovis is a 
member of the Mycobacterium tuberculosis complex (Mtbc) which also includes M. 
tuberculosis, M. caprae, M. microti, M. africanum, M. canetti, M. pinnipedii, M. suricattae, M. 
mungi, and M. bovis Bacillus Calmette Guerin (BCG) 1-3. Despite what the nomenclature may 
imply, members of this group are not host species specific. The host range of M. bovis appears 
to be the broadest of the complex, causing disease in a number of species including humans 4. 
Great strides have been made over the past century both toward the control of bovine 
tuberculosis (bTB) in cattle and also limiting the risk to human exposure (e.g., pasteurization of 
milk for dairy products); however, the disease still has great socioeconomic impact for 
livestock farmers. It is estimated that over 50 million cattle are currently infected worldwide, 
costing around $3 billion annually5. The WHO (World Health Organization), in conjunction 
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with FAO (Food and Agriculture Organization of the United Nations) and OIE (Office 
International des Épizooties), classify bTB as a neglected zoonosis 6,7. 
A crucial component of the immune response to TB in humans, cattle and mice is the 
production of interferon (IFN)-γ by T helper 1 (Th1) CD4 T cells 8-12. Immune deficiencies 
affecting CD4 T cells [e.g., human immunodeficiency virus (HIV) infection] and IL-12/IFN-γ 
/STAT1 signaling pathways result in more severe disease upon TB infection in humans 13,14. In 
fact, IFN-γ release assays (IGRA) and delayed type hypersensitivity (i.e., skin test) responses 
are markers of infection in cattle and humans (reviewed respectively by Schiller et al. 15 and 
Walzl et al. 16). Diagnostic IGRAs are measures of ‘ex vivo’ immune responses relying on 
rapid production of IFN-γ in response to mycobacterial antigen stimulation in short-term (16–
24 h) whole blood or peripheral blood mononuclear cell (PBMC) cultures. These ex vivo assays 
are generally considered a measure of T cell effector responses 12,17. Most protective bTB 
vaccines elicit ex vivo IFN-γ responses; however, not all vaccines inducing this response are 
protective 5,18. Cultured assays (i.e., culture of cells for 7-14 days before IFN-γ measurement) 
are assumed to quantify memory responses, primarily central memory T cells (Tcm) in humans 
19-21. In light of the idea that cultured ELISPOT measures Tcm responses, several studies have 
shown its association with protection against malaria, suppression of viral recrudescence in 
hepatitis B virus carriers, low virus levels in HIV infection, and favorable outcomes in human 
TB 22-26. In cattle, responses measured by cultured IFN-γ ELISPOT following vaccination are 
the best-known positive correlate of protection in vaccine and challenge experiments 27-31. 
Increasing interest has risen in order to characterize and assess the role of 
polyfunctionality in both protective and detrimental immune responses in TB. Polyfunctional T 
cells simultaneously produce two or more cytokines with IFN-γ, IL-2, and tumor necrosis 
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factor-α (TNF-α) being the most commonly measured Th-1 cytokines 32,33. Association 
between protection and vaccination-induced polyfunctional T cells has been mainly studied in 
small animal models 34,35. In humans, strong polyfunctional responses are detected in M. 
tuberculosis-infected individuals, high IL-2 production is associated with a positive clinical 
status (e.g., latent or treated disease), while a strong IFN-γ/TNF-α response is associated with a 
poor outcome (i.e., active TB) 36. Human polyfunctional responses to vaccination both prior to 
TB exposure and in previously exposed individuals (i.e., latent infection) are extremely 
variable. In cattle, T cell polyfunctionality has only been measured upon ex vivo recall 
stimulation 26,37.These studies found no association between polyfunctional responses measured 
before challenge and vaccine success. Instead, polyfunctional responses to infection were 
associated with increased pathology and poor disease outcome 26. Polyfunctional responses by 
long-term cultured cells for enrichment of Tcm responses have not been evaluated in spite of 
the fact that cultured IFN-γ ELISPOT is one of the most promising protection correlates in 
cattle 27-31. 
The research included in this thesis had the objective to characterize memory cells 
phenotype and aspects of their functionality in cattle, specifically in response to bTB infection 
and vaccination. The discrimination of cell phenotype involved in cytokine production under 
both cultured and ex vivo conditions may be necessary to identify specific correlates of vaccine 
efficacy, useful for vaccine candidates selection for costly efficacy trials in biosafety level 3 
(BSL-3) facilities. 
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Literature Review 
 
CD4 T cell activation and function 
Naïve CD4 T cells are primarily activated by mature antigen-loaded dendritic cells 
(DCs) in the T-cell areas of secondary lymphoid organs and the ensuing response is influenced 
by this initial interaction 38. The clonal expansion that follows CD4 T-cell activation is 
accompanied by cell differentiation 39,40 both of which increase the precursor frequency in 
comparison to the naïve pool and results in greater ability of these cells to support CD8 and B 
cell responses. CD4 T cells are essential for B-cell germinal center formation, class switching 
and affinity maturation (such cells are defined as T follicular helper cells) 41. CD4 T cells act 
via cytokine production and CD40L expression 41-43. CD4 T cells also influence general 
immune responses, as their interactions with DCs are bi-directional, tailoring the activation of 
other cells38. Although CD8 T cells certainly can be activated in the absence of CD4 T cells, 
CD4 cells are essential for CD8 T cells long-term persistence and  proliferative ability 42-45. 
Fundamentally, CD4 cells play a major role for the optimal response of both CD8 T cells and 
B cells, and in their ability to establish memory.  
Classically, antigen clearance is associated with the contraction phase, in which the 
majority of antigen-specific T cells are eliminated 46,47. A small pool, however, become 
memory cells (Fig. 1). Considerable efforts have been made to identify markers that distinguish 
cells that will overcome the contraction phase to become memory from short-lived effector 
cells 40,45,48-62. Memory development is associated with higher expression of survival signals 
[e.g., IL-7 receptor alpha chain (CD127) and B-cell lymphoma 2 protein (BCL-2) expression 
on activated CD4 T cells] and lower expression of inhibitory receptors, such as the killer cell 
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lectin-like receptor G1 (KLRG-1) and programmed cell death protein 1(PD-1) (reviewed by 
Mahnke et al. 47).  
 
 
Figure 1. Kinetics of T cell primary responses. Upon antigen recognition, naïve T cells 
proliferate (during the expansion phase) and differentiate into effector cells. If infection is 
controlled, short-lived cells will be eliminated over the next several weeks (contraction 
phase). Only a small percentage of cells generated during the expansion phase (5–10%) 
survive and further develop into memory T cells. This process increases response fitness 
and yields higher precursor frequency (depicted as the gray dashed line) in comparison 
with primary immune response.  
 
The strength of the signal through the T-cell receptor (TCR) has also been investigated 
and may influence CD4 T cell fate, with cells bearing higher affinity TCR outcompeting cells 
bearing lower affinity TCRs 48,49. The role that self-peptide and MHC class II (pMHC), as 
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presented by antigen presenting cells (APCs), plays in memory T cell survival has also been 
the aim of extensive investigation. Experimentally, CD4 memory cells can survive in the 
absence of pMHC signaling, but whether this is also possible in vivo has been a matter of 
debate 52 .Jenkins  et al. 40 demonstrated that TCR transgenic memory cells declined at a faster 
rate in a dose dependent fashion with transfer of increasing numbers of cells. Elevated numbers 
of cells would increase the competition for the same pMHC and other survival signals leading 
to speedy decline. Other factors, such as the signals present during T-cell priming, can also 
affect the long-term survival of memory cells. For example, immunization with antigen and 
Toll-like receptor 2 (TLR2) agonists generated memory cells that survived in greater numbers 
than those generated by immunization with the same antigen and a TLR4 agonist 53. Cells with 
different fates may arise from the same progenitor cells, even though these cells bear TCR of 
the same affinity54. Harrington  et al.55 demonstrated that genetically marked IFN-γ producing 
CD4 T cells during a primary response were present in the subsequent memory pool. 
Relatedly, Lohning et al.56 demonstrated that adoptively transferred cytokine-producing 
antigen-specific T cells are capable of becoming memory cells in recipient mice, indicating 
that not all effector cells are short lived and may become memory cells. 
Certainly, antigen clearance appears to be crucial for memory formation under several 
circumstances. However, memory cells may arise soon after cell priming. Lauoar  et al. 57 
demonstrated the appearance of CD8 memory cells during the acute phase of a primary 
response to lymphocytic choriomeningitis virus (LCMV) as early as eight days after infection. 
Likewise, prime-boost vaccination with viral-vectored subunit malarial vaccine antigens 
induces both ex vivo and cultured IFN-γ ELISPOT responses by seven days 58. Memory cells 
are also elicited during chronic infections, and although antigen clearance has crucial role in 
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response kinetics, pathogen clearance in some infections, such as TB (including M. bovis 
infection in calves), is not always naturally achievable.  
Truly, the very factors governing effector / memory T cell differentiation remain largely 
unknown59. Whether memory cells arise (Figure 3): (a) as direct progenies of effector cells 
(linear differentiation model 60-62), (b) via a linear process dictated by a progressive loss of T 
cell differentiation potential (i.e., from naïve à memory à effector à terminally 
differentiated cells) dependent on antigenic stimulation and signaling milieu (decreasing 
potential model 56,63) or (c) as a separate lineage from naïve cells (divergent differentiation 
model 54,57,) has long been debated. Still, the connection between naïve CD4 T cells and the 
various effector and memory fates these cells follow remains unclear, and a single unifying 
theory accounting for the diversity of CD4 T cell memory has not been determined. This 
suggests that CD4 T cell memory generation may be differentially engaged depending on 
various factors (e.g., level of inflammation, TCR affinity), and these models might not be 
mutually exclusive. Although many differences between memory and effector cell populations 
have been described, especially at the population level, technologies to drive memory T cell 
generation remain an elusive field. 
 
Memory cells subsets: a growing family 
The notion of immunity has been likely observed since ancient times through the 
observation of natural resistance and differences in disease severity presented by different 
individuals and animals. Thucydides, a Greek historian (460 BCE), gave perhaps the first 
documented evidence of immunological memory when he noticed that people who had 
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recovered from a new disease brought to Greece from Spartans during the Peloponnesian war 
would not “be attacked twice - never at least fatally” 65. 
 
Figure 2. Models for T cell heterogeneity generation. A. Separate-precursor model, naive T 
cells are pre-programmed to follow a differentiation path; cell fate is determined during thymic 
development. B. Decreasing-potential model suggests that effector T cells adopt various 
differentiation states according to the cumulative history of signals that they encounter during 
infection. Repetitive stimulation with antigen and other signals, such as interleukin-2 (IL-2) 
and IL-12, drives greater effector cell proliferation and terminal differentiation. As the cells 
acquire terminally differentiated states they remain functional but lose memory cell properties, 
such as survival, plasticity and proliferative potential. The formation of heterogeneous effector 
cell populations is dependent on the overall 'strength' of the signals that are encountered early 
during T cell priming and throughout the infection. C. Asymmetric cell fate model states 
effector and memory T cell arise from a single precursor T cell through asymmetric cell 
division that occurs as early as the first cell division after antigen stimulation. Proximity with 
APCs may play a role in determining the cell fate of the daughter cells. (Adapted from: Kaech 
and Cui 64). 
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In the 18th century, Ludwig Panun, a Danish physician, perceived that the 
immunological memory to measles could persist for a lifetime. He drew this conclusion 
observing two measles outbreaks occurring 65 years apart in an isolated island in the North 
Sea; individuals who had the disease in the first outbreak were not susceptible to re-infection 
66. Interestingly, the very concept of immunity was described much earlier than the 
understanding of both the immune system itself and microorganisms. Still the mechanisms 
governing immunological memory, especially T cell memory, are vastly unknown.  
The ability to remember antigenic encounters and provide protection against pathogens 
are the foundation and the main goal of vaccination. Development of memory is a complex 
process, and so are memory T cells. In fact, memory comprises many subsets with distinct 
homing potentials and effector functions. Sallusto and colleagues 67 studied the expression of 
two lymph node homing receptors on CD45RA negative memory T cells: CC chemokine 
receptor type 7 (CCR7) and CD62L. Lymph node endothelial cells express CCR7 ligands: 
chemokine (C-C motif) ligand (CCL)-19 and -21. Consequently, the expression of CCR7 
expression allows cells to follow its ligands gradient, guiding these cells to the T cell zone 
within lymph nodes. Increased CD62L expression facilitates T cell entrance into lymph nodes 
as its ligand, glycam-1, is highly expressed on high endothelial veins (HEV). The CD45 
antigen has a cytoplasmic domain that, in T cells, eliminates the inhibitory phosphate groups 
on the tyrosine kinase Lck, promoting cell activation. Alternative splicing of the CD45 gene 
produces as many as eight different proteins: CD45RA, CD45RB, CD45RC, CD45RAB, 
CD45RAC, CD45RBC, CD45RO, CD45R (ABC). The most well known isoforms are 
CD45RA and CD45RO and depending on the activation status, these two isoforms are 
differentially expressed in T cells 68-71. Naïve T cells express the larger CD45RA isoform, 
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while lacking CD45RO expression. Upon antigenic recognition, T cells switch the expression 
of CD45RA to the expression of the CD45RO isoform. The CD45RO isoform is smaller, as it 
lacks the RA, RB, and RC exons, easing the cell activation 71. 
In their experiments, Sallusto and colleagues67 described two subsets of memory T cells 
with distinct functionality: Tcm and Tem cells. Cells from both subsets express CD45RO and 
lack CD45RA. Tcm cells express CCR7 and CD62L, and are mainly located in T-cell areas of 
secondary lymphoid organs. Tcm cells have limited effector function, but show low activation 
threshold and retain high IL-2 production and proliferative capacity. Tem cells lack CCR7 and 
display receptors for homing to peripheral or inflamed tissues. Effector cells do not express 
CCR7 and express little to no CD62L, but promptly produce effector cytokines, such as IFN-γ. 
These cell subsets have also been detected in mice67 cattle 72 and non-human primates 73,74. 
Due to their peripheral localization, tissue-resident memory T cells (Trm) were not 
identified until recently 75 .Trm cells are confined to peripheral non-lymphoid tissues and they 
may be present long after the initial infection has been cleared, providing an immediate 
frontline adaptive response if a similar pathogen is reencountered at the entry site. In general, 
these cells express low levels of CCR7 and CD62L, and high levels of local non-lymphoid 
tissue-homing molecules such as CD103 and CD69. Trm cells seldom recirculate, explaining 
why studies investigating memory cells in the peripheral blood and secondary lymph organs 
(SLOs) failed to detect Trm cells 76,77. 
Zhang and colleagues78, studying graft-versus-host disease (GVHD) in mice, reported 
the existence of a subset of self-renewing CD8 T cells able to generate Tcm, Tem and effector 
T cells. The GVHD was observed upon transfer of these self-renewing cells to irradiated 
recipient mice, indicating their role in the disease. The phenotype of these cells was defined as 
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CD8 cells displaying low expression of the CD44 marker (an activation marker) and high 
expression CD62L and has been called stem-cell memory T cells (Tscm). This phenotype was 
later reported in humans and in non-human primates 79-82. These cells maintain some naïve T 
cells characteristics, such as self-renewing capacity and plasticity. Although, human Tscm cells 
were first identified as a CD8 T 81 cell population, CD4 T cell were later shown to generate 
Tscm cells 82. Tscm cells are not very numerous, only 2–3% of T cells from peripheral blood of 
healthy donors, and their identification relies on complex multiparameter flow cytometry cell 
analysis. The Tscm phenotype is described as 
CD45RA+CD45R0−CCR7+CD62L+CD27+CD28+ CD95high. The intriguing expression of CD95 
on Tscm cells raises the possibility of a new role for that receptor, indicating it may be 
important for the function and/or persistence of these cells 80,81. Analysis of antigen-specific 
CD8 Tscm cells demonstrated that they retain self-renewal capacity while also exhibiting rapid 
cytokine production upon antigen re-exposure82. Transcriptional analysis of human CD4 Tscm 
cells indicates that Tscm cells are a transitional differentiation stage between naïve and Tcm 
cells 82. In non-human primates, Tscm cells are distributed in peripheral blood, secondary 
lymphoid organs, and bone marrow 81. After in vitro stimulation, Tscm cells often maintain 
their phenotype. When compared with Tcm cells, this self-renewing capability is twice as 
frequent in Tscm cells than in Tcm cells cultures80. Tscm cells exhibit high survival capability 
even in the absence of cognate antigens81. Not surprisingly, Tscm cells highly express pro-
survival transcription factors (e.g., BCL2, Myeloid Cell Leukemia 1 protein -MCL1; and 
Lymphoid Enhancer-Binding Factor 1- LEF1) as compared to the other memory subsets and 
are able to differentiate into other memory subsets, including Tcm 81,82. No other memory 
subset has been found to regenerate Tscm cells. 
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An obvious complication to the study of memory cells is the variability of markers and 
conditions under which their responses are assessed. The differential expression of a collection 
of molecules conferring lymphocyte functions is shown in Table 1. The multiple memory 
subsets are defined by differential function they exhibit due to the expression of these multiple 
molecules involved in migration, co-stimulation, cytotoxicity, and adhesion.  
In cattle, memory responses have long been studied through the use of the antigen 
experienced splice variant marker CD45RO, activation markers (such as:CD25, CD69, MHC-
II and CD26) and homing molecules (Table 2). Often, the measured responses were assumed to 
be due to memory cells by the timing of the assessment (the ensuing response upon an 
expected antigen clearance). Yet, Tcm and Tem subsets have only recently been characterized 
76. In cattle, Tcm have been shown to have a higher proliferative capacity than Tem and 
effector counterparts. Still, Trm and Tscm subsets have not been investigated in cattle. 
Applied vaccinology has comprised the majority of immunological memory assessment 
in veterinary species. As most protective vaccine often rely on the neutralizing antibodies, 
serologic responses are frequently assessed immune parameter 83-86. Cellular immune responses 
in cattle have mostly been studied through cytokine production by non-fractionated peripheral 
blood mononuclear cells (PBMC) and due to restrictions on reagent availability and research 
support, less sophisticated cell population analysis (i.e., flow cytometry) is often performed86-
90. Frequently, memory responses are assessed through antigen clearance, typically achieved in 
vaccination or acute infection settings. These approaches are very useful, especially for vaccine 
development, but they provide limited advancement to the veterinary immunology field, and 
for the development of better tools to troubleshoot vaccine failure.  
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Table 1. Expression of functional molecules by circulating naïve and memory 
murine T-cell subsets according to differentiation stages 
 
 
 
 
Category Antigen Function Naïve Tscm Tcm Tem
CD28 Costimulation + ++ ++ −
CD27 Costimulation ++ + + −/+
CD127 IL-7 signaling ++ +++ +++ −/+
PD-1
Inhibition of 
effector function
−
−/+ +
+
CD122
IL-2/IL-15 signaling −
+ ++
+++
CD132
γc cytokine 
signaling
+
+ +
+
KLRG-1
Inhibition of 
effector function
−
ND −/+
++
HLA-DR
Peptide presentation −
− −/+
+
CD38
Calcium flux/signal 
transduction
+
−/+ −
−
CD69 Proliferation − − − −
Ki-67 Proliferation − − −/+ −/+
CD11a
Adhesion to 
APC/endothelium
+
++ ++
+++
CD58 Adhesion to APC − + ++ +++
CD99
Transendothelial 
migration
−/+
+ ++
++
CD62L
Secondary 
lymphoid tissues 
homing
+
+ +
−
CD103
Gut homing / 
Residency
−
− −
+
CCR4
Chemokine 
response/Th2 
associated
−/+
+ ++
+++
CCR5
Homing to inflamed 
tissues
−
− +
+++
CCR6
Chemokine 
response/Th17 
associated
−
− ++
+++
CCR9 Gut homing − ND + −
CCR10 Skin homing − − + ++
CXCR3
Homing to inflamed 
tissues
−
−/+ +
+++
CXCR4
Homing to bone 
marrow
+
++ +++
++
CLA Skin homing − ND + ++
Granzyme A
Cleavage of cellular 
proteins
−
− −
−/+
Granzyme B
Cleavage of cellular 
proteins
−
− −
−/+
Perforin Pore forming − − − −/+
CD161
Regulation of 
proliferation/cytoto
xicity
−
− −/+
+++
IL-18Ra Response to IL-18 − −/+ + +++
c-Kit Response to SCF − − − +++
CD130 Response to IL-6 ++ + −/+ −
Miscellaneous
Costimulation/
survival
Activation
Adhesion
Migration
Cytolytic 
molecules
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Table 2. Studies evaluating memory T cell in cattle and parameters analyzed. 
 
 
Disease / model Method Cell marker Cell function Reference
Whole or cell-free 
colostrum fed calves, 
impact in their responses 
to vaccines
Flow cytometry CD45RO CD62L CD4 Phenotype, memory 89
Oenothein B stimulation Flow cytometry CD45RO IFN-γ , GM-CSF production 90
M. bovis, M. avium 
Paratuberculosis CD45RO, CD25, CD26 Cell activation 91
Foot and mouth disease CD45RO CD25 gd T cells 92
Vaccines against 
Contagious Bovine 
Pleuropneumonia
Flow cytometry, IFN-γ 
ELISPOT, ELISA CD45R, CD45RO, CD62L IFN-γ, proliferation 93
Impact of aging Flow cytometry, IFN-γ ELISPOT, ELISA
CD4, CD45RO, CD62L, 
IFN-γ
Memory (as assessed by 
Cultured ELISPOT), IFN-γ 
production
94
M. bovis infection Flow cytometry, IFN-γ ELISPOT
CD4, CD44, CD62L, 
CD45RO, CCR7,  IFN-γ
IFN-γ production, cell 
proliferation 72
M. bovis BCG vaccination 
and challenge
Flow cytometry, ELISA, flow 
cytometry CD4, IFNγ, TNFα, IL-2 Cytokine production 24
M. bovis BCG Flow cytometry, cultured IFN-γ ELISPOT, ELISA CD4, IFN-γ
Memory response (as 
assessed by Cultured 
ELISPOT), IFN-γ 
production
30
M. bovis DeltaRD1 and 
challenge
Cultured IFN-γ ELISPOT, 
IFN-γ ELISA rtPCR ( IFN-γ 
and IL-17)
None
Memory response (as 
assessed by Cultured 
ELISPOT), IFN-γ and IL-17 
expression.
27
M. bovis BCG followed 
by Viral booster  and 
challenge
Flow cytometry, cultured IFN-
γ ELISPOT, ELISA
CD4, CD8; CD25, γδ TCR,  
MHC class II
Cell activation, memory (as 
assessed by Cultured 
ELISPOT), proliferation, 
cytokine production
28
M. bovis Flow cytometry
CD8, CD45RO, 
gammadelta TCR,  
proliferation, IFN-γ
Proliferation, cyottoxicity 95
M. bovis-BCG Flow cytometry, rtPCR (IL-4, IL13, IL-21)
CD4, CD45RO, CD62L, 
IFN-γ Cytokine production 96
M. bovis
CD4, CD8, gammadelta 
TCR   CD45RO, CD26, 
CD25, proliferation
Cell activation, proliferation 97
Babesia bovis
 Flow cytometry, Northern 
Blotting, ELISA (IL-2, IL-4, 
IFN-γ) 
CD2, CD4, CD8, CD45R, 
CD45RO, CD62L
Cell activation, cytokine 
production 98
Theileria parva
Flow cytometry, cell sorting, 
rnaPCR (IL-2, IL-4, I, 
CD45), ELISA (IFN-γ)
 CD2, CD4, CD8, 
gammadelta TCR,WC1, 
WC3,CD45RO+
Cytoknine production, 
proliferation, cell activation 99
Bovine viral diarrhea virus Flow cytometry  CD4, CD8, CD25, CD45RO, CD62L
Cell expansion and 
populational size in BAL 100
 	
15	
Fortunately, advancements are being made in the field of veterinary immunology 
through increased reagent availability, more accessible technologies, and due to the revived 
appreciation for One Health approaches. These developments will likely prove to be useful for 
human research as well, especially for zoonotic pathogens, and to diseases to which laboratory 
models poorly recapitulate aspects of the disorder seen in humans and other primary host 
species. 
 
Phenotype and function 
The paradigm of segregating T cells into Tcm and Tem on the basis of their expression of CC-
chemokine receptor 7 (CCR7) or CD62L, along with CD45RA67, not only provided a 
conceptual advance in our understanding of T-cell dynamics and compartmentalization, it also 
enabled the identification of distinct patterns of cytokines (that is, IFN-γ and IL-2) associated 
with these specific subsets of memory T cells. In fact, both phenotype and function of these 
specific subsets provide two independent facets of the immune response and combined are 
more informative whether such responses in regards to protection predition. Although Tcm 
cells are prone to express IL-2, whereas Tem cells produce more IFN-γ, that dichotomy is not 
unconditional. In HIV-infected adults receiving chemotherapy, up to 80% of the IL-2-
producing CD4+ T cells specific for antigens from CMV, influenza virus, EBV, HSV or the 
HIV gag protein are Tem cells 101-103. Similarly, in mice infected with Leishmania major 104 or 
humans infected with vaccinia virus 105-107 the majority of IL-2 was produced by 
multifunctional CD4+ Tem cells. In cattle, natural M. bovis infection elicits strong 
polyfunctional T cell responses almost exclusively by CD62Llo CD4 cells 37. Also, Tcm and 
Tem cells may produce all combinations of IFN-γ, IL-2, and TNF-α under long-term culture 
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condition. Several factors that influence the fate outcome, such as the relative frequency of 
Tem versus Tcm cells, the amount and duration of the antigen persistence, innate immunity, 
clonal competition and the characteristic of the pathogen. These factors will impact CD4 T cell 
memory, influence the predominant source of IL-2 and of other cytokines, contributing to cell 
functionality and infection outcome. In summary, evaluating the quality of a T cell response in 
combination with analysis of their phenotype increases the understanding of T cell memory 
and effector differentiation by defining the T cell functional capacity, strength and trafficking. 
Hence, a combined phenotypic and functional analysis of T cells should allow greater insight 
into whether a response is protective than either parameter alone, still, analysis of these 
parameters should always be analyzed taking in consideration the overall response and the 
nature of the infection. 
 
The case for TB 
Mycobacterium tuberculosis remains one of the most detrimental human pathogens and 
has been challenging to combat due to the lack of an effective vaccine. M. tuberculosis has co-
evolved with humans for more than 70,000 years, resulting in the earth's most successful 
bacterial pathogen capable of establishing itself within its host for decades as a latent infection. 
It is estimated that more than 2 billion people worldwide are infected with M. tuberculosis with 
greater than 8.6 million developing acute pulmonary tuberculosis (TB) and about 1.3 million 
dying from the disease every year. TB infection ranks second among infectious diseases 
causing human deaths, only after HIV. Moreover, the emergence of multidrug-resistant 
(MDR), extensively drug resistant (XDR), and total drug-resistant (TDR) M. tuberculosis 
strains have increased the need for an effective vaccine 36. Bovine tuberculosis (bTB) is a 
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chronic bacterial infection that affects animals and humans. Mycobacterium bovis, the main 
agent causing bTB, is a member of the Mycobacterium tuberculosis complex1-4. Zoonotic 
transmission of M. bovis occurs primarily via ingestion of unpasteurized dairy products or 
contact with infected cattle5. Before pasteurization became a common practice, infection with 
M. bovis resulted in up to 25% of TB cases in humans. The disease also has significant 
socioeconomic implications for livestock farmers with estimates of >50 million cattle infected 
worldwide, costing $3 billion annually5. The WHO (World Health Organization), in 
conjunction with FAO (Food and Agriculture Organization of the United Nations) and OIE 
(Office International des Épizooties), recently classified bTB as a neglected zoonosis 6,7. Early 
discoveries in the field of TB indicate that the success of disease control in human populations 
would depend on the success of control measures in animals, and vice versa. Recognizing the 
zoonotic importance of a cattle-derived pathogen, eradication / control programs were initiated 
in many developed countries in the late 1800s. While costly and laborious, bTB control 
programs have generally been successful with a few notable exceptions (e.g., UK and Ireland). 
The resulting near disappearance of zoonotic TB from the human population exemplifies one 
of the largest One Health successes in medical history5.  
Numerous advances in TB diagnosis, vaccinology, molecular epidemiology and 
immunopathogenetic studies have been made within the disciplinary divides of human and 
animal health research. More recently, the discovery of similarities in the interactions between 
the natural hosts and the causative agents of TB, as well as similarities in the resulting disease, 
have led to a renewed appraisal of the benefits of collaborative approaches. For example, as a 
control measure, the currently approved vaccine against TB, BCG, is an attenuated strain from 
M. bovis. As with BCG, typical vaccination approaches aim to mimic the natural immune 
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response to infection using an attenuated pathogen expressing antigens broadly overlapping the 
antigen profile of the pathogenic agent. This approach has, in fact, resulted in the development 
of several highly successful vaccines against acute infections, to which natural immune 
response to infection is sufficient to protect against future infections, enabling eradication of 
pathogens, such as smallpox and rinderpest 108. While BCG has been a valuable tool to prevent 
severe disease in children, it has failed to protect adults against TB infection and prevent active 
disease, especially in countries where the disease is endemic. Currently, there is a significant 
effort toward the development of a new TB vaccine 36. Even though BCG reduces disease 
incidence in children, neither BCG nor prior infections promote an immune response sufficient 
to prevent disease reactivation or reinfection; the lack of protection emphases the challenge of 
developing a vaccine against an infection that requires cellular immunity to contain an 
established infection.  
Untiringly, the majority of M. tuberculosis infected individuals will contain the 
infection and never develop clinical disease, supporting that sterile immunity can be usually 
achieved, which is supported by the observations of healed TB lesions at autopsies, from which 
no cultivable bacteria is isolated, suggesting that M. tuberculosis clearance occurred 109. 
Nevertheless, several reports suggest that the absence of clinical TB is not a clear sign of sterile 
immunity. These reports include: (i) the fact that infected individuals maintain cellular 
responses to TB antigens for long periods of time, (ii) the finding of clinical isolates from the 
same from the same individuals taken years apart displaying identical genotype110, and (iii) the 
isolation of M. tuberculosis DNA in fatal transit victims with no TB signs or history 111; 
suggesting that sterile immunity may be less common than originally assumed. Moreover, 
reactivation of latent infection is frequently the cause of recurrent TB, especially under low-
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endemic settings 112,113. Even in high-incidence regions, only ∼9% of recurrent TB cases in 
immune competent individuals is caused by re-infection. In this scenario, a vaccine able to 
stimulate long-term containment of infection preventing contagious lung disease rather than 
infection, would still undoubtedly represent an advance and impact disease control and global 
health36. 
BCG attenuation was a 13-year process, taking over 230 serial passages 114. The 
genomic deletions responsible for BCG attenuation resulted in 16 genomic regions of 
differentiation (RD1–RD16, plus nRD18) as compared to the M. tuberculosis genome. All 
BCG strains lack RD1, a 9.5 kb DNA segment that encodes immunodominant T cell antigens 
including ESAT-6, CFP-10, Rv3873, and PPE protein. The attenuation gave rise to different 
BCG strains 115. It was distributed worldwide as a TB vaccine for humans: BCG Russia 
(ATCC 35740), BCG Moreau/Rio de Janeiro, BCG Tokyo, BCG Sweden, BCG Birkhaug 
(ATCC 35731), BCG Denmark 1331 (ATCC 35733), BCG China, BCG Prague, BCG Glaxo 
(ATCC 35741), BCG Tice (ATCC 35743), BCG Frappier (ATCC 35735), BCG Connaught, 
BCG Phipps (ATCC 35744), and BCG Pasteur 1173. The search for better vaccines has 
included recombinant BCG (rBCG) and prime boost strategies using viral vector or subunits 
strategies investigation. rBCG strategy has mainly focused on  the construction of: (a) 
Overexpression of  immunodominant antigens already expressed by BCG, such as α-crystallin: 
HspX, and antigen 85 (Ag85) complex proteins (Ag85A, Ag85B, and Ag85C); (b) insertion of 
immunodominant antigens not expressed by BCG, such as RD1, RD2, RD3, RD14, RD15, 
RD16, and nRD18 encoded antigens; (c) both, overexpression and insertion of genes lost 
throughout attenuation; (d) BCG modification targeting cytokine production and 
immunomodulation5. The numerous BCG sub-strains with different attenuation levels and 
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antigenic repertoires, as well as the recombination process used may have profound influence 
on rBCG vaccine efficacy. Interestingly, pre-clinical animal (including cattle) and human 
studies have not supported that BCG strains provide different protection levels 29- 31, in spite of 
eliciting different cytokine levels. 
A major complication for developing a successful vaccine is the current lack of a gold 
standard of a fully protective immunological response in TB5,36. The use of better animal 
models, such as cattle, to more precisely reflect pathogenesis and ensuing immune responses in 
humans would be helpful for the understanding of the disease and perhaps its control. To 
achieve disease control in humans and animals, it will be paramount to exceed the prevalent 
focus on Th-1 cytokines, especially IFN-γ, and assess a wide range of immune parameters. 
This will allow signatures to be identified for correlation to vaccine success or failure. In the 
meantime, the search for better and safer vaccines should be continued. A future vaccine 
strategy able to hamper transmission (in human or cattle) and/or the establishment of infection 
would represent not only an improvement compared to BCG, but one of the biggest 
achievements in modern vaccinology. 
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Abstract 
 
Effector and memory T cells are generated through developmental programing of naïve 
cells following antigen recognition. If the infection is controlled up to 95 % of the T cells 
generated during the expansion phase are eliminated (i.e., contraction phase) and memory T 
cells remain, sometimes for a lifetime. In humans, two functionally distinct subsets of memory 
T cells have been described based on the expression of lymph node homing receptors. Central 
memory T cells express C-C chemokine receptor 7 and CD45RO and are mainly located in T-
cell areas of secondary lymphoid organs. Effector memory T cells express CD45RO, lack 
CCR7 and display receptors associated with lymphocyte homing to peripheral or inflamed 
tissues. Effector T cells do not express either CCR7 or CD45RO but upon encounter with 
antigen produce effector cytokines, such as interferon-γ. Interferon-γ release assays are used 
for the diagnosis of bovine and human tuberculosis and detect primarily effector and effector 
memory T cell responses. Central memory T cell responses by CD4+ T cells to vaccination, on 
the other hand, may be used to predict vaccine efficacy, as demonstrated with simian 
immunodeficiency virus infection of non-human primates, tuberculosis in mice, and malaria in 
humans. Several studies with mice and humans as well as unpublished data on cattle, have 
demonstrated that interferon-γ ELISPOT assays measure central memory T cell responses. 
With this assay, peripheral blood mononuclear cells are cultured in decreasing concentration of 
antigen for 10 to 14 days (long-term culture), allowing effector responses to peak and wane; 
facilitating central memory T cells to differentiate and expand within the culture.  
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Introduction 
 
Effector and memory T cells are generated through developmental programing of naïve 
CD4+ T cells after antigen recognition. Differentiation of naïve CD4+ T cells into cytokine 
producing cells requires pathogen recognition by innate immune cells, antigen presentation to 
T cells, co- stimulation and transcriptional changes resulting in polarized cytokine production. 
For example: antigen presenting cells produce interleukin (IL)-12 in response to intracellular 
pathogens, which, together with antigen recognition, promotes differentiation of T cells into T 
helper 1 (Th1) cells1,2 by signaling through signal transducer and activator of transcription 4 
(STAT4) and T-box expressed in T cells (T-bet), leading to cell activation, IL-2 production, 
clonal expansion and interferon (IFN)-γ production3,4. If the infection is controlled, up to 95 % 
of the T cells generated during the expansion phase are eliminated (i.e., contraction phase) and 
memory T cells remain, sometimes for a lifetime5. Sallusto et al.6, revealed two functionally 
distinct subsets of memory T cells in humans based on the expression of lymph node homing 
receptors. Central memory T cells (Tcm) express C-C chemokine receptor (CCR)-7 and 
CD45RO and are mainly located in T-cell areas of secondary lymphoid organs. Tcm have 
limited effector function, a low activation threshold and retain high IL-2 production and 
proliferative capacity. Effector memory T cells (Tem) express CD45RO, lack CCR7 and 
display receptors for homing to peripheral or inflamed tissues. Effector cells do not express 
either CCR7 or CD45RO but promptly produce effector cytokines, such as IFN-γ, upon antigen 
recognition. 
IFN-γ release assays (IGRA) are used for the diagnosis of bovine and human 
tuberculosis7. Mycobacterium bovis is the principal agent of bovine tuberculosis (bTB) while 
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human cases of tuberculosis are caused mainly by Mycobacterium tuberculosis. With these 
tests, whole blood or peripheral blood mononuclear cells (PBMC) are stimulated with 
mycobacterial antigens for 16 to 24 hr and IFN-γ production within the supernatant is 
measured by ELISA or through detection of cells producing IFN-γ using ELISPOT techniques. 
As a result of the brief stimulation period (i.e., 16 to 24 h) and rapid cytokine production, ex 
vivo assays detect primarily effector and Tem responses. This has been confirmed by flow 
cytometric analysis of cell populations in these cultures8-10. 
Ex vivo IFN-γ responses are routinely included within the immune response panel 
evaluation of tuberculosis vaccines, including those used to evaluate responses by cattle. Most 
effective bovine tuberculosis vaccines elicit specific IFN-γ responses, but not all vaccines that 
induce IFN-γ responses are protective. Also, levels of IFN-γ elicited by vaccination, as 
measured before infection, do not necessarily correlate with protection. For instance, different 
BCG strains may have different capacities to induce ex vivo IFN-γ response, in spite of similar 
protection levels11. Thus, ex vivo IGRAs are valuable for tuberculosis diagnosis and for 
accessing vaccine immunogenicity; however, their use as predictors of vaccine efficacy is 
limited. Tcm responses to vaccination, on the other hand, may be used to predict vaccine 
efficacy, as demonstrated with simian immunodeficiency virus (SIV) infection in non-human 
primates12,13, tuberculosis in mice14 and malaria in humans15,16. 
After an effective immune response resulting in pathogen clearance, Tcm are maintained 
and provide protection to an eventual second infection by the same agent. A notable exception 
to this scenario is M. tuberculosis infection of humans in which patients receiving curative 
anti-mycobacterial therapy are susceptible to re-infection17,18. Additionally, events governing 
immunological memory during chronic infections, wherein the antigenic stimulation persists, 
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are not well understood19. During chronic infections, such as with human immunodeficiency 
virus (HIV) and tuberculosis, a significant Tcm response is associated with a favorable 
outcome (e.g., latency with tuberculosis and subclinical disease with HIV)20,21. Several studies 
with mice and humans have demonstrated that long-term cultured IFN-γ ELISPOT assays 
measure Tcm responses16,20-22. With this assay, PBMCs are cultured in decreasing 
concentration of antigen for 10 to 14 days, allowing effector responses to peak and wane; 
facilitating Tcm to differentiate and expand within the culture. 
Long-term cultured IFN-γ ELISPOT assays have also been used in veterinary research, yet 
the phenotype of responding cells has been difficult to assess due to a lack of critical reagents, 
especially an antibody to CCR7. Effective bovine tuberculosis vaccines [e.g. using a single 
dose of M. bovis Bacille Calmette Guerin (BCG), BCG followed by viral-vectored Antigen 
85A subunit vaccine, or attenuated M. bovisΔRD1] elicit long- term cultured IFN-γ ELISPOT 
responses following vaccination that correlate with protection (i.e., lower mycobacterial burden 
and decreased TB- associated pathology) against subsequent challenge with virulent M. 
bovis23,24. Furthermore, the numbers of antigen-specific IFN-γ-secreting cells within long-term 
PBMC cultures are higher at 12 months but decrease at 24 months after BCG vaccination of 
neonatal calves, correlating with the degree of protection detectable post M. bovis challenge25. 
In this scenario, the cultured IFN-γ ELISPOT is an important tool for predicting vaccine 
efficacy, providing a means to prioritize vaccine candidates for high cost efficacy trials. 
Additionally, cultured ELISPOT techniques can be adapted for various hosts, pathogens and 
cytokines by altering antigens or antibodies for a variety of purposes in different research 
fields. 
 
 	
42	
Protocol 
 
1. Prepare the following solutions: 
1.1. Prepare complete RPMI (cRMPI) by adding fetal bovine serum (FBS) to a 
concentration of 10 % (volume / volume), glutamine (2 µM), sodium pyruvate (1 µM), 
non-essential amino acids (0.1 µM), penicillin–streptomycin (100 units / ml penicillin 
and 0.1 mg / ml streptomycin) and 2-mercaptoethanol (50 mM) into RPMI 1640. 
 
1.2. Prepare 2 X acid citrate dextrose, by mixing sodium citrate (77 µM), citric acid 
(38 µM), and dextrose (122 µM), in distilled water. 
 
1.3. Prepare Ca2+ Mg2+ free phosphate buffered saline (PBS) pH 7.2: NaCl (137 mM), KCl 
(2.7 mM), Na2HPO4 (dibasic, 10 mM), KH2PO4 (monobasic, 2 mM) in distilled water; 
adjust the pH to 7.2. 
 
1.4. Prepare PBS 1% (PBS 1 % BSA) by adding bovine serum albumin into PBS (volume / 
weight, 1g / 100mL of PBS). 
 
1.5. Prepare PBS + 0.05 % tween 20 (PBST) by adding 0.05 % tween 20 into PBS (volume 
/ volume, 500 l of tween 20 / l L of PBS). 
 
1.6. Prepare 100 mM Tris HCL pH 8.2 buffer by mixing Tris (100 mM), HCl (0.50 mM) in 
distilled water. 
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1.7. Prepare 35 % ethanol solution by diluting ethyl alcohol (purity ≥99.5%) in distilled 
water (volume / volume, 35 ml of ethyl alcohol / 100 ml of distilled water). 
 
1.8. Filter sterilize cRPMI, 2 x acid citrate dextrose, PBS, PBS 1 % BSA using 0.22 m 
filters. 
 
2. Long-term cultured cells (14 day protocol) 
(Day one) 
2.1 Prepare antigen solutions at twice the final concentration in cRPMI. Antigen choice is 
critical and should be tailored to the purpose of the study. 
 
2.2 Dilute recombinant M. tuberculosis antigens TB10.4 and antigen Ag85A to 2 g / ml (of 
each antigen; the final concentration is 1 g / ml). 
 
2.3 Dilute M. bovis purified protein derivative (PPD-B, Prionics Ag) to 10 g / ml (the final 
concentration is 5 g / ml). 
 
2.4 Dilute the recombinant early secretory antigenic target 6 (ESAT-6) and culture filtrate 
protein 10 (CFP-10) fusion protein (rESAT-6:CFP10) to 2 g / ml (final concentration of 1 g 
/ ml).  
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NOTE: These antigens are immunodominant IFN-γ inducing antigens of tuberculous 
mycobacteria and may be included to stimulate PBMC from M. bovis infected animals. BCG 
or M. bovis RD1 vaccinated animals do not respond to rESAT-6:CFP10, as the region 
encoding these antigens (i.e., RD1) is deleted in these strains. rESAT-6:CFP10 used in these 
study was a  kind gift from Dr. C. Minion, Iowa State University. TB10.4 and antigen Ag85A 
are immunodominant antigens present in virulent and vaccine M. bovis strains 37.  PPDB, as a 
purified protein derivative, is a complex of several antigens including antigens shared with 
non-tuberculous mycobacteria. Infected animals will potentially respond to all antigens 
(namely: TB10.4, Ag 85A, rESAT-6:CFP10 and PPDb), while vaccinated animals should not 
respond to rESAT-6:CFP10 11. 
 
2.5 Plate 500 l / well of antigen solution in quadruplicates for each animal in a 24 well plate. 
For this protocol, use antigens as a pool; thus use all wells contain all the antigens and no 
controls (such as, null or mitogen) this step. Incubate plate at 39 °C / 5 % CO2. The normal 
temperature of cattle is 39 °C; thus, some investigators utilize 39 °C for culture of bovine 
cells. Also, in certain instances with human cells, cell culture at 39 °C provides added 
benefit26,30. 
 
2.6 Pre-load syringes coupled with 16 or 18 gauge hypodermic needles with 6 ml of 2 X acid-
citrate-dextrose;  and  collect 60 ml of bovine blood by jugular venipuncture. 
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2.7 Isolate PBMC by standard density gradient centrifugation of the peripheral blood buffy 
coat fractions adjusting cell concentration to 4 X 106 cells / ml as described by Maue et al. 
27 
 
2.8 Add cells (500 l / well) into antigen preloaded 24 well plate, in quadruplicate for each 
animal (step 2.5). Incubate plate at 39 °C / 5 % CO2. 
 
(Days three and seven) 
 
2.9 Using sterile technique, carefully remove 500 l of the supernatant from each well without 
disturbing the cell layer. 
 
2.10 Replenish well volume by adding 500 l / well of cRPMI containing IL-2  (30 U / l, i.e., 15 
U / well; recombinant human IL-2 Sigma I7908). Incubate plate at 39 °C / 5 % CO2. 
 
(Days 10 and 12) 
 
2.11 Using sterile technique, remove 750 l of supernatant from each well. Replenish the 
volume with 750 l / well of cRPMI (without IL-2). Incubate plate at 39 °C / 5 % CO2. 
 
3. ELISPOT assay  
Day one / 12th day of Long-term culture protocol 
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3.1 Label the ELISPOT plate properly for each set of samples, to avoid mistakes when plating 
cells: long-term cells plus antigen presenting cells (APCs), long-term cells without APCs 
and ex vivo / short-term cells (Figure 1). Replicates for each treatment (i.e. antigenic 
stimulation) should be done at least in duplicate. 
 
3.2 Prepare capture antibody solution by diluting mouse anti-bovine IFN-γ antibody 
(MCA2112, clone CC330) in PBS (8 g / ml). 
 
3.3 Using a multichannel pipettor pre-wet the wells of the ELISPOT plate with 15 l / well of 35 
% ethanol for 1 min. To prevent membrane damage, do not touch the bottom of wells with 
pipette tips at any point during the assay. 
 
3.4 Wash plate six times with 300 l / well of PBS. Wash fluid should be discarded by plate 
inversion. Washes should be done rapidly, not allowing plate wells to dry. 
 
3.5 Pipette 100 l / well of capture anti-IFN-γ antibody (from step 1 above). Incubate at 4 °C 
overnight (keep the plate inside a zippered storage bag). 
 
Day two / 13th day of the long-term culture protocol 
 
3.6 Prepare antigen solutions at twice the final concentration. Treatments are: no stimulation 
(cRPMI), PPD-B (20g / ml, final concentration: 10g / ml), protein cocktail of TB10.4 and 
Ag85A (2 g / ml of each protein, final concentration: g / ml of each protein), rESAT-
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6:CFP10 (for M. bovis infection, 2 µg / ml, final concentration: 1 g / ml), and a positive 
control, such as pokeweed (20 g / ml, final concentration: 10 g / ml). Other mitogen may be 
used instead of PWM (e.g., Concanavalin A). 
 
 NOTE: for this step antigens compose four different treatments and are not used as a pool (as 
in step 2.5). The four treatments are: NS, PPDb, protein cocktail (TB10.4 and Ag85A 
constitute one treatment) and PWM.  
 
4. Short-term cell culture and adherent cell (APCs) isolation 
4.1 Collect 60 ml blood from the same animals bled on day 1 (under: long-term culture, 14 day 
protocol) and isolate PBMCs as before. 
 
4.2 Adjust cell concentration to 2 X 106 cells / ml. Label tubes clearly to prevent misallocation 
when plating cells. These cells will be used for APCs isolation and also as short-term cell 
culture (step 6.5).  Label tubes with both the animal number and the type of culture (in this 
case: ex vivo, short-term or fresh cells). 
 
4.3 Remove excess capture antibody from the ELISPOT by plate inversion. Wash plates 6 
times with 300l PBST. 
 
4.4 Remove as much PBST as possible. Pipette 50 l of cell suspensions to the wells labeled as 
long-term cells plus APCs. Block other wells with 200 l / well of cRPMI. Incubate 90 min 
at or 39 °C. Pre-warm cRPMI to or 39 °C (necessary for subsequent steps). Fresh PBMCs 
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not used for adherent cell (APCs) isolation will be needed in subsequent steps and should 
be stored. 
 
5. Cultured cells 
5.1 During the 90 min incubation (step 4.4, short-term culture and adherent cell isolation step), 
harvest long-term cultured cells. 
 
5.2 Using 5 or 10 l pipettes, pipette media with cells up and down to detach cells, combine the 
quadruplicate replicates from each animal into a single 15 ml tube. Centrifuge the tubes for 
5 min at 400 g. 
 
5.3 After centrifugation, discard the supernatant by tube inversion. Dislodge cell pellet. Add 5 
ml of PBS, gently re-suspend pellet, if necessary. Repeat the centrifugation. Repeat the 
washing step twice. Discard supernatant by tube inversion and gently re-suspend cells in 
1ml cRPMI. Adjust cell concentration to 2 X 105 cells / ml.  
 
6. Plating fresh and cultured PBMCs 
6.1 After the 90 min incubation, shake plates on plate shaker for 30 seconds. Remove non-
adherent cells by plate inversion. Pipette 150 l / well of warm cRPMI (from step 4, under: 
Short-term cells and adherent cell (APCs) isolation step). 
 
6.2 Shake plates and discard wash fluid. Repeat wash 3 times. Add 100 l / well of each antigen 
into appropriate wells (pre-labeled). 
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6.3 To plate cells, pipette 100 l / well of long-term cultured cell suspension (2 x 105 cells / ml) 
into the wells labeled as long-term cells plus APCs. Ensure that the long-term cells added 
in this step are from the same animal as the APC’s already in the well. Do not mix APC’s 
and long-term cultured cells from different animals. 
 
6.4 Pipette100 l / well of the long-term cultured cell suspension (2 x 105 cells / ml) into wells 
without APCs for assessment of APC requirement to the long-term culture response. 
 
6.5 Add 100 l / well of short-term cells (freshly isolated and adjusted to 2 x 106 cells / ml) for 
ex vivo response assessment. Incubate plates overnight at 39 °C / 5 % CO2 incubator. 
Ensure that plates are lying flat and do not stack plates. 
 
NOTE: If analysis of cell phenotype is desired, flow cytometry can be performed as an 
ancillary assay. Cells are plated in 96 well U bottom plates (instead of ELISPOT plates) as 
described for ELISPOT assay. Capture antibody adsorption (steps 3.4 to 3.5) should be 
skipped. Cells are then incubated overnight at 39 °C / 5 % CO2 and a standard cell staining 
protocol performed. Cell staining reagents are included in the reagents table. 
 
Day three (14th day of the Long-term culture protocol) 
 
6.6 Dilute detection antibody (mouse anti-bovine IFN-γ, clone CC302) to 5 g / ml in PBS 1 % 
BSA. Discard fluids from wells and wash plates: six times with PBST (300 l / well), 
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placing on shaker each time for 10 sec before and in-between washes, once with dH2O (300 
l / well), an additional 6 times with PBST (300 l / well) and two times with PBS (300 l / 
well). After cells are removed from the plates, and if no biosafety concerns apply, 
procedures may be performed outside biological safety cabinets.  
 
6.7 Discard wash fluid. Remove as much wash fluid as possible by tapping plate on paper 
towels. Add detection antibody (100 l / well). 
 
6.8 Incubate plates for 120 min at or 39 °C. During this incubation step, prepare alkaline 
phosphatase solution following the manufacturer's instructions. Thirty min before use (i.e., 
90 min after addition of detection antibody to wells) dilute the reagent in PBST. Invert the 
tube gently to mix reagents and incubated at room temperature.  
 
6.9 After the 120 min incubation, discard excess detection antibody by plate inversion.  Wash 
plate 6 times with PBST (300 l / well). Remove as much wash fluid as possible by tapping 
plate on paper towels.  
 
6.10 Add 100 l / well of alkaline phosphatase solution (from step 3 above). Incubate plates for 
45 min at room temperature. Discard fluid and wash each plate 6 times with PBST (300 l / 
well). 
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6.11 Prepare the substrate solution following the manufacturers' instructions (Vector Blue AP 
substrate III): Dilute reagents in 100 mM Tris HCL pH 8.2 buffer. Pipette 50 l / well of the 
substrate solution. 
 
6.12 Incubate at room temperature until blue color starts to develop (approximately 30 min). 
Discard fluid and wash plates with copious amounts of dH2O. Remove bottom plate to 
expose membrane, wash back of wells and allow plate to air dry. 
 
6.13 Read plates on immunospot image analyzer or ELISPOT reader (Table 1), or manually, 
using a stereomicroscope. Alternatively, keep plates in dark at room temperature until 
reading. Because of the high stability of the reaction substrate, quality is preserved for 
several years. 
 
NOTE: Cells and antigen concentrations were optimized to avoid wells with uncountable spots 
23,24,27,37. It is possible that uncountable spots formation occur in different settings or due to 
biological variation. If that is the case, cell concentration should be optimized so a readable 
spot counting is obtained. 
 
7. Plates reading and data analysis 
7.1 Perform analysis as per the Cellular Technology Limited (CTL) ELISPOT plate reader 
guide (Table 1). After the spots counts are obtained for each of the wells, calculate the average 
between duplicates. The specific immune response to each antigenic stimulus is calculated by 
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subtracting the average number of spots in non-stimulated wells from that of antigen-
stimulated wells. 
 
Table 1 AutoImmun Diagnostika ELISPOT reader image 
acquisition and cell counting procedure.  
 
 
 
Representative Results 
 
Approximately one-month post-aerosol infection with M. bovis (104 colony-forming 
units), PBMCs from infected (n=8) and control animals (n=8) were cultured in the presence of 
antigens and IL-2 for 13 days. Development of Tcm responses after infection was determined 
using IFN- ELISPOT assay. Representative Tcm (in the presence or absence of APCs) and ex 
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vivo IFN-γ ELISPOT responses from infected animals (Three animals) and a non-infected 
animal (one animal) are shown in Figure 1. A successful long-term IFN- γ ELISPOT assay 
results in cells producing IFN-γ (Spot-Forming Cells, SFC) under stimulated conditions and 
near absence of a response from non-infected animals and under non-stimulated conditions. 
Also, a strong T cell response should occur in response to PWM. Specific responses to M. 
bovis were assessed by PPD-B or rESAT-6:CFP10  antigenic stimulation. As shown in Figure 
1, robust Tcm and ex vivo responses to PPD-B and rESAT-6:CFP10 were detected from all 
three M. bovis-infected animals. Minimal to no Tcm and ex vivo responses were detected from 
the control animal.  
 
Figure 1 Image of wells from a long-term cultured IFN-γ ELISPOT assay. 
Cultured IFN-γ ELISPOT assay was performed approximatelyone month after challenge with 
virulent M. bovis (three animals). Non-infected animals were included as controls (one 
animal). Long-term cell lines were generated by stimulating PBMC with a cocktail of 
recombinant Ag85A (1 µg / ml), TB10.4 (1 µg / ml), rESAT-6:CFP10 (1 µg / ml) and PPD-B 
(5 µg / ml) for 13 days followed by transfer to ELISPOT plates in the presence or absence of 
autologous APC. Short-term cells consisted of PBMC isolated on day 13 and plated directly 
into ELISPOT plates. Long- term and short-term cells were stimulated with PPD-B (10 µg / 
ml), rESAT-6:CFP10 (1 µg / ml), medium alone or pokeweed mitogen (5 µg / ml) for 24 h.  
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Figure 2 Representative results from a long-term cultured IFN-γ ELISPOT 
response to M. bovis purified protein derivative (PPD-B).  Cultured IFN-γELISPOT 
assay was performed approximately one month after challenge with virulentM. bovis 
(eight animals). Non-infected animals were included as controls (eight animals Long-
term cells were generated by stimulating PBMC with a cocktail of recombinant Ag85A 
(1 µg / ml), TB10.4 (1 µg / ml), rESAT-6:CFP10 (1 µg / ml) and PPD-B (5 µg / ml) for 
13 days followed by transfer to ELISPOT plates in the presence or absence of 
autologous APCs. Short-term cells consisted of PBMC isolated on day 13 and plated 
directly into the ELISPOT plate. Long-term and short-term cells were stimulated with 
PPD-B (10 µg / ml) or medium alone for 24 h. Specific responses from each animal 
(SFC / 106 cells) are presented as response to PPD-B (average of duplicate samples) 
minus the response to media alone.  
 
 
Discussion 
 
Assessment of Tcm responses is also feasible by sorting these cells from PBMC. Direct 
enrichment of Tcm from PBMC, however, requires expensive devices, highly trained personal 
and is difficult as these cells are not numerous in the blood stream. Long-term culture of 
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PBMC provides enrichment of Tcm over Tem and effector cells without expensive devices; 
however, because these T cell populations are expanded in vitro they may be less 
representative of in vivo memory responses. It is possible to access IFN- memory responses 
(using the long-term culture or Tcm sorting strategies) by assays other than the ELISPOT such 
as: cytokine ELISAs34, cytokine bead arrays (CBA), intracellular staining (ICS), or cytokine 
protein arrays (CPA). These methods; however, are generally less sensitive than ELISPOT 
assays35. 
An advantage of ELISPOT is its ability to detect the immediate capture of the cytokine 
shortly after its release preventing dilution in the supernatant and degradation by enzymatic 
cleavage or cytokine uptake by other cells. ELISPOT assays detect single cells producing 
cytokines providing precise results even in low signal to noise scenarios (i.e. low specific 
responses)35. Also, with ICS, detection of cytokines prior to release may result in false 
identification of cells producing cytokines (e.g., due to post-translational modulation before or 
during the secretory process)34. The transport inhibitors employed with ICS assays to minimize 
cytokine secretion during antigen stimulation (known as Golgi stop proteins) limit the duration 
of cell stimulation due to the cell toxicity of these proteins ultimately impacting cytokine 
production35.  
With that said - CBA, CPA and ICS are useful techniques for measuring multiple 
cytokines simultaneously and / or for determining cell surface marker expression (i.e., with 
ICS). Therefore, these methods may be used in combination with the IFN-γ ELISPOT assay36. 
While previous bovine TB vaccine efficacy studies measured Tcm responses via ELISPOT 
assay, the detection of Tcm responses by other techniques will likely yield comparable results. 
Importantly, the ELISPOT assay is less expensive and simpler to perform than CBA, CPA and 
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ICS analysis techniques34. Manual counting of the SFC is an alternative to automated counting, 
and ELISPOT plates can be stored at room temperature for long period of time with minimal 
quality loss, before or after spot counting37 
The long-term cultured IFN-γ ELISPOT response has been applied to assess memory 
responses by human, and cattle when evaluating tuberculosis vaccine responses14-16,31-32,33. 
Tcm responses are also assumed to play significant roles in host responses to several other 
infectious agents of cattle, such as: Mycoplasma mycoides subsp. mycoides42, Anaplasma 
marginale38 and bovine respiratory syncytial virus39. Potentially, the long-term ELISPOT assay 
might be adapted for other animal species, cytokines and infections. These broader applications 
will be especially useful for veterinary immunology applications due to current limited 
availability of specific reagents. 
Tcm responses are crucial for protection against several infections, but measuring them 
early after infection / immunization (for disease outcome prediction or vaccine efficacy) may 
be cumbersome. Analysis of the immune response under ex vivo and short antigenic 
stimulation conditions will more often represent effector responses, due to the overlap of 
memory and effector responses, especially during the beginning of immunological memory 
formation. In the context of chronic diseases in which the antigen load is continual, ex vivo 
responses will assess effector cell responses or a combination of memory and effector cell 
responses. The long-term cultured IFN- ELISPOT assay, described here, likely enables the 
measurement of Tcm responses rather than effector T cell or combined CD4+ T cell responses. 
In summary, the long-term cultured IFN- ELISPOT assay provides a valuable approach for 
estimating T cell memory responses and has been employed successfully to evaluate memory 
responses of several species to a variety of infections agents12-16, 20-25,29,31,33,34,38,39. 
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Abstract 
 
Cultured IFN-γ ELISPOT assays are primarily a measure of central memory T cell 
(Tcm) responses with humans; however, this important subset of lymphocytes is poorly 
characterized in cattle. Vaccine-elicited cultured IFN-γ ELISPOT responses correlate with 
protection against bovine tuberculosis in cattle. However, whether this assay measures cattle 
Tcm responses or not is uncertain. The objective of the present study was to characterize the 
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relative contribution of Tcm (CCR7+, CD62Lhi, CD45RO+), T effector memory (Tem, defined 
as: CCR7-, CD62Llow/int, CD45RO+), and T effector cells (CCR7-, CD62L-/low, CD45RO-), in 
the immune response to Mycobacterium bovis. Peripheral blood mononuclear cells (PBMC) 
from infected cattle were stimulated with a cocktail of M. bovis purified protein derivative, 
rTb10.4 and rAg85A for 13 days with periodic addition of fresh media and rIL-2. On day 13, 
cultured PBMC were re-stimulated with medium alone, rESAT-6:CFP10 or PPDb with fresh 
autologous adherent cells for antigen presentation. Cultured cells (13 days) or fresh PBMCs (ex 
vivo response) from the same calves were analyzed for IFN- γ production, proliferation, and 
CD4, CD45RO, CD62L, CD44, and CCR7 expression via flow cytometry after overnight 
stimulation. In response to mycobacterial antigens, ~75% of CD4+ IFN-γ+ cells in long-term 
cultures expressed a Tcm phenotype while less than 10% of the ex vivo response consisted of 
Tcm cells. Upon re-exposure to antigen, long-term cultured cells were highly proliferative, a 
distinctive characteristic of Tcm, and the predominant phenotype within the long-term cultures 
switched from Tcm to Tem. These finding suggest that proliferative responses of Tcm cells to 
some extent occurs simultaneously with reversion to effector phenotypes (mostly Tem). The 
present study characterizes Tcm cells of cattle and their participation in the response to M. 
bovis infection. 
 
Introduction 
 
Bovine tuberculosis (bTB) is a chronic bacterial disease of animals that may also infect 
humans. Mycobacterium bovis, the main agent causing bTB, is a member of the 
Mycobacterium tuberculosis complex, which also comprises: M. tuberculosis, M. canettii, M. 
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africanum, M. pinnipedii, M. microti, M. caprae and M. mungi [1, 2]. This genetically related 
group of bacteria causes TB with comparable pathology in a wide variety of hosts [3, 4]. Great 
strides have been made over the past century in the control of bTB in cattle and to limit the risk 
to humans (e.g., pasteurization of milk for dairy products); however, the disease persists as a 
significant socioeconomic hardship for livestock farmers with estimates of >50 million cattle 
infected worldwide, costing $3 billion annually. The WHO (World Health Organization), in 
conjunction with FAO (Food and Agriculture Organization of the United Nations) and OIE 
(Office International des Épizooties), recently classified bTB as a neglected zoonosis. 
An essential component of the immune response to TB in humans, cattle and mice is 
the production of IFN-γ by T helper 1 (Th1) CD4 T cells [5-10]. Immune deficiencies affecting 
CD4 T cells (e.g., HIV infection) and IL-12/IFN-γ /STAT1 signaling pathways result in more 
severe disease upon TB infection in humans [11,12]. Given the importance of Th1 cells in the 
immune response to TB, it is not surprising that IFN-γ release assays (IGRA) and delayed type 
hypersensitivity (i.e., skin test) responses are useful correlates of infection (reviewed by 
Schiller et al. [13] for cattle and Walzl et al. [14] for humans). Widely utilized in IGRAs, early 
secretory antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10) are potent 
inducers of Th-1 cytokines [15]. ESAT-6 and CFP-10 are co-secreted proteins encoded by the 
RD-1 region of the genome of M. tb complex mycobacteria. Such genes are absent in all M. 
bovis bacillus Calmette Guerin (BCG) strains and most other non-tuberculous mycobacteria 
species [16-19]. Diagnostic IGRA’s are measures of ‘ex vivo’ immune responses relying on 
rapid production of IFN-γ in response to mycobacterial antigen stimulation in short-term (16 – 
24 hrs) whole blood or peripheral blood mononuclear cell (PBMC) cultures. Ex vivo assays for 
use in bTB diagnosis are generally considered a measure of T cell effector responses and are 
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frequently used to measure immune responses to bTB vaccines prior to and after challenge 
with virulent M. bovis [9,20]. While most protective bTB vaccines elicit ex vivo IFN-γ 
responses, not all vaccines that induce this response provide protection [21]. Additionally, 
levels of IFN-γ elicited by vaccination do not necessarily correlate with the level of protection 
afforded by the vaccine [22]. Thus, the identification of correlates of protection is needed to 
prioritize vaccine candidates for evaluation in costly BL-3 vaccination/challenge efficacy trials. 
Recent vaccine efficacy studies in cattle have demonstrated that long-term cultured 
IFN-γ ELISPOT (so called, cultured IFN-γ ELISPOT) responses are positive predictors of 
vaccine efficacy [23-25] and duration of immunity [26]. Protection provided by vaccination is 
partial and protected animals have reduced mycobacterial burden and associated pathology 
following experimental infection. In this assay, PBMCs are stimulated with antigens for 10-13 
days and maintained by fresh media exchange and exogenous IL-2. After this initial culture 
period, cells are re-stimulated for an additional 20 hrs in the presence of autologous antigen 
presenting cells (APC) in anti-IFN-γ coated ELISPOT plates. Studies with samples from 
humans have demonstrated that cultured ELISPOT responses are primarily a measure of T cell 
memory (Tcm) cells [27-29]. 
Sallusto et al. [30] identified two functionally distinct subsets of memory T cells (i.e., 
CD45RA-/CD45RO+) in mice and humans based on expression of the lymphoid homing 
receptors CD62L and CCR7. These two subsets are: (1) Tcm cells which express CD62L and 
CCR7 and are preferentially located in lymphoid tissues and (2) effector memory T (Tem) cells 
which lack CD62L and CCR7 expression and are preferentially located in peripheral tissues or 
remain blood associated, either circulating or contained within splenic red pulp or hepatic 
sinusoids [31]. Tem cells show immediate effector functions, maintaining preformed cytotoxic 
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granules for rapid cytolysis of infected host cells [32]. Tcm cells show elevated proliferation 
and IL-2 production capabilities, being able to generate Tem and effector cells [33] whereas 
Tem cells undergo relatively little proliferation and secrete minimal IL-2 upon restimulation 
[28,31,33]. While Tcm and Tem have different roles in the immune response, both subsets are 
thought to be important for protection against pathogens. Still, due to the high proliferative 
capacity and long life span of Tcm, the eliciting of Tcm is believed to provide long-term 
protection.  
The cultured ELISPOT assay measures memory responses, primarily Tcm in humans 
[27-29]. Godkin et al. [27] tracked hepatitis C virus HLA-DR11-restricted epitopes in the 
course of the long-term culture, demonstrating that cultured ELISPOT IFN-γ production was 
due to long-lived CD4+ Tcm expressing CCR7. The fundamental role of CCR7+ CD4 cells was 
also reported by Todryk et al. [34]; these authors assessed the effect of depletion of CCR7 
expressing cells on ex vivo or cultured ELISPOT responses to either  influenza antigenic 
peptides or M. tb purified protein derivative (PPD). The depletion of CCR7+ cells dramatically 
reduced cultured ELISPOT responses, yet had only a minimal effect on ex vivo responses. 
Supportive of the idea that the cultured ELISPOT response is a measure of Tcm responses, 
several studies have shown the association of responses measured by this assay with protection 
against malaria, suppression of viral recrudescence in hepatitis B virus carriers, low viremia in 
human immunodeficiency virus (HIV) infection, and favorable outcomes in human TB [28,35-
38]. 
While responses measured by cultured IFN-γ ELISPOT following vaccination correlate 
to protection with bTB; the phenotype of the responding cells within the long-term cultures has 
not been determined for cattle in response to neither vaccination nor infection. A better 
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understanding of the cattle immune system may enable the development of improved vaccine 
strategies and consequently, greater protection against this zoonotic disease of cattle. In the 
present study, we characterize effector and memory T cell subsets in the immune response to 
M. bovis infection of cattle.   
 
Materials and methods 
 
Animal Use Ethics  
All studies were approved by the National Animal Disease Center Animal Care and 
Use (Protocol #’s ACUP-2508 and ACUP-2688) / Institutional Biosafety (Permit #’s IBC-
0285A and IBC-0004RA) committees and performed under appropriate project licenses within 
the conditions of the Animal Welfare Act originally signed into law in 1966 and in accordance 
with the most recent amendments. All animals were housed in appropriate biological 
containment facilities at the National Animal Disease Center. Animals did not develop clinical 
signs of bTB (such as: cough, dyspnea, anorexia and weight loss); however, one animal (from 
the non-infected control group) was euthanized by intravenous administration of sodium 
pentobarbital due to an umbilical infection. 
 
Mycobacterium bovis aerosol challenge procedures 
Two field strains of M. bovis were used for challenge inoculum: 95-1315 (Michigan 
white-tailed deer isolate) and 10-7428 (Colorado dairy isolate). Low passage (≤ 3) cultures of 
both strains were prepared using standard techniques in Middlebrook 7H9 liquid media 
(Becton Dickinson, Franklin Lakes, NJ) supplemented with 10% oleic acid-albumin-dextrose 
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complex (OADC) plus 0.05% Tween 80 (Sigma, St. Louis, Missouri). Holstein steers (~ 6 
months of age) were obtained from a bTB-free herd in Sioux Center, IA and housed in a 
biosafety level-3 (BSL-3) facility at NADC in separate rooms based upon treatment group. For 
the first experiment, treatment groups consisted of non-infected steers (n = 7) and animals 
receiving 104 colony-forming units (cfu) of M. bovis 95-1315 (n = 8), or M. bovis 10-7428 (n = 
8). For the second study, a single group of steers (n=8) received 104 cfu M. bovis 10-7428. For 
both studies, M. bovis challenge inoculum was delivered to restrained calves (~9 months of 
age) by aerosol as described by Palmer et al. [39]. Briefly, inoculum was nebulized into a mask 
(Trudell Medical International, London, ON, Canada) covering the nostrils and mouth, 
allowing regular breathing and delivery of the mycobacteria to the lungs via the nostrils. The 
process continued until the inoculum, a 1 ml PBS wash of the inoculum tube, and an additional 
2 ml PBS were delivered - a process taking ~10 min. Strict biosafety protocols were followed 
to protect personnel from exposure to M. bovis throughout the study, including BSL-3 
containment upon initiation of M. bovis challenge in animal rooms and standard laboratory 
practices for handling M. bovis cultures and samples from M. bovis-infected animals. 
 
Mycobacterial isolation and assessment of lesions 
All calves were euthanized ~4 months after challenge by intravenous administration of 
sodium pentobarbital. Tissues were examined for gross lesions and processed for microscopic 
analysis and isolation of M. bovis. Tissues collected included: lung; liver; mandibular, parotid, 
medial retropharyngeal, mediastinal, tracheobronchial, hepatic, and mesenteric lymph nodes. 
Lymph nodes were sectioned at 0.5 cm intervals and examined. Each lung lobe was sectioned 
at 0.5 – 1.0 cm intervals and examined separately. Lungs and lymph nodes (mediastinal and 
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tracheobronchial) were evaluated using a semi-quantitative gross pathology scoring system 
adapted from Vordermeier et al.[9]. Tissues collected for microscopic analysis were fixed by 
immersion in 10% neutral buffered formalin. For microscopic examination, formalin-fixed 
tissues were processed by standard paraffin-embedment techniques, cut in 5 µm sections and 
stained with hematoxylin and eosin. Adjacent sections from samples containing caseonecrotic 
granulomata suggestive of bTB were stained by the Ziehl-Neelsen technique for identification 
of acid-fast bacteria. Microscopic tuberculous lesions were staged (I-IV) based on a scoring 
system developed by Wangoo et al. [40]. 
 
Ex vivo and long-term cell culture 
PBMC were isolated from buffy coat fractions of blood collected in 2× acid-citrate-
dextrose solution. Complete RPMI medium for PBMC cell culture was RPMI 1640 (GIBCO, 
Grand Island) supplemented with 2 mM L-glutamine, 25 mM HEPES buffer, 100 units/ml 
penicillin, 0.1 mg/ml streptomycin, 1% non-essential amino acids (Sigma, St. Louis, MO), 2% 
essential amino acids (Sigma), 1% sodium pyruvate (Sigma), 50 mM 2-mercaptoethanol 
(Sigma), and 10% (v/v) fetal bovine sera (FBS). Long-term cell cultures were generated by 
stimulating 2 × 106/ml PBMC with a cocktail of M. bovis PPD (PPDb, 5 µg/ml, Prionics Ag, 
Sclieren, Switzerland) rAg85A (1 µg/ml, LIONEX Diagnostics and Therapeutics GmbH, 
Braunschweig, Germany), rTB10.4 (1 µg/ml, LIONEX Diagnostics and Therapeutics GmbH), 
and rESAT-6/CFP-10 (1 µg/ml, kind gift from Chris Minion, Iowa State University) in 
complete RPMI medium. Cells were cultured (2 × 106cells/well, 1ml/well) in 24 well flat-
bottom microtiter plates (Nunc, Thermo Fisher, Waltham, MA). Media containing human rIL-2 
(Sigma, 10 U/ml) was used to replace media from the PBMC cultures at days 3 and 7. Fresh 
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media without IL-2 was used at days 10 and 12. For ELISPOT assays, at day 13, cultured cells 
were added (2 × 104 of cultured PBMC/well) to anti-bovine IFN-γ capture-mAb (Serotec, 
Oxford, UK) coated 96-well ELISPOT plates (Millipore, Watford, UK) and incubated in the 
presence of autologous APCs and either PPDb (5 µg/ml), rESAT-6:CFP10 (1 µg/ml), 
pokeweed mitogen (PWM, Sigma) (1µg/ml) or medium alone. Autologous APCs were isolated 
by adherence incubating 1 × 105 freshly isolated PBMC in complete medium at 39°C/5% CO2 
for 90 min in ELISPOT plates. Non-adherent cells were discarded and the adherent cells 
(APCs) washed four times with warm RPMI 1640 media. Fresh complete media containing 
antigen and long-term cultured cells were then incubated 20h at 39°C/5% CO2. For flow 
cytometric analysis, cultured cells were added (2 × 104 of cultured PBMC/well) to round-
bottom well plates and incubated in the presence of APCs and either PPDb (5 µg/ml), rESAT-
6:CFP10 (1 µg/ml), PWM (1µg/ml) or medium alone. Autologous APCs were prepared as 
described for the ELISPOT assay. Fresh complete media containing antigen and long-term 
cultured cells were then incubated 16h at 39°C/5% CO2 with Brefeldin A (Sigma, 10µg/ml) 
added at 4h of culture. 
 
IFN-γ ELISPOT 
The IFN-γ ELISPOT assay was performed as described by Vordermeier et al. [41] and 
Whelan et al., [25]. Briefly, polyvinyldifluoride 96-well ELISPOT plates (Millipore) were 
coated at 4°C overnight with an anti-bovine IFN-γ capture mAb (Serotec), followed by a 
blocking step (10% fetal bovine serum (FBS) in RPMI 1640 media, 2h, 39°C/5% CO2). 
Autologous APCs were isolated by adherence on coated and blocked ELISPOT plates. Long-
term cultured cells (2 × 104 of cultured PBMC/well) were added to ELISPOT plates (Millipore, 
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Watford, UK) and incubated with either PPDb (5 µg/ml), rESAT-6:CFP10 (1 µg/ml), PWM 
(1µg/ml) or medium alone for 20h at 39°C/5% CO2. Spot forming cells (SFC) were detected 
following the VECTASTAIN® ABC-AP Kit (Vector Laboratories, Burlingame, CA) standard 
procedures.  
 
Flow Cytometry  
Following the appropriate culture duration, cells were pooled from individual animals 
according to in vitro treatments (i.e., stimulation). Cells were stained as described by Maue et 
al.,[42] with the primary antibodies and appropriate secondary antibodies listed on the Table 1. 
CD4 T cells were analyzed as a separate panel, while CD8 and γδ T cells staining was 
performed together to enable the analysis of CD8 expressing γδ T cells. Intracellular staining 
was performed following BD Perm/Wash instructions (BD Biosciences, San Jose, CA). 
 
Table 1 Primary and secondary monoclonal antibodies and proliferation staining reagents 
 
For cell-trace labeling, cells were labeled with CellTrace Violet (Invitrogen, Carlsbad, 
CA) following kit instructions. Briefly, either freshly isolated or long-term cells (cultured for 
13 days) were resuspended at 1 × 107 cells in PBS containing 10 µM/ml of the cellTrace dye 
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with immediate vortexing to ensure rapid homogenous staining of cells. Staining was 
performed at 20°C and cell were incubated for 5 min. Cells were washed three times with PBS 
containing 10% FBS and cultured for additional six days in the presence of APCs and antigens 
in round-bottom 96-well plates before cell staining with primary and secondary antibodies. For 
the long-term cultured cells the culture length was 19 days. Flow cytometric analysis was 
performed with a BD LSR flow cytometer (BD Biosciences). Data were analyzed using 
FlowJo (Tree Star Inc., San Carlos, CA). 
 
Statistical analysis 
Data were analyzed using Analysis of Variance followed by Tukey’s or Šídák’s  
multiple comparisons test or Student’s t test using GraphPAD Prism 6.0 (GraphPAD Software 
Inc., La Jolla, CA). 
 
Results 
 
Aerosol M. bovis infection of cattle elicits long-term cultured IFN-γ ELISPOT responses 
Aerosol inoculation to cattle with M. bovis 95-1315 or M. bovis 10-7428 resulted in a 
similar distribution and severity of gross and microscopic tuberculous lesions as well as 
mycobacterial colonization, primarily affecting the lungs and lung-associated lymph nodes 
[43]. Specific cell-mediated and antibody responses, including kinetics of the response as well 
as antigen recognition profiles, were also comparable between the two treatment groups 
[43,44].  
With bTB vaccine efficacy studies, long-term cultured (i.e., 14 days) IFN-γ ELISPOT 
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responses to vaccination (i.e., BCG, M. bovis ΔRD1, and viral-vectored Ag85) negatively 
correlates with mycobacterial burden and TB-associated pathology and positively correlates 
with vaccine-induced protection [23-25]. As with vaccination, M. bovis infection also elicited 
long-term cultured IFN-γ ELISPOT responses in cattle (Fig. 1). Three weeks after infection, 
long-term cultured IFN-γ ELISPOT responses by PBMCs from infected cattle to rESAT-
6:CFP10 and PPDb exceeded (P < 0.05) respective responses by PBMCs from non-infected 
calves (Fig. 1A). Similar results were detected with ex vivo (i.e., short-term) responses (Fig. 
1B). Also, Tcm and ex vivo responses did not differ (P > 0.05) between M. bovis 95-1315- and 
10-7428-infected groups (Fig. S1). The weak response detected to PPDb by non-infected cattle 
in both ex vivo and long-term cultures was likely due to prior exposure to non-tuberculous 
mycobacteria (NTM, a common occurrence in US dairy cattle) as pre-infection whole blood 
(18 hr stimulation) IFN-γ responses to M. avium PPD (PPDa) exceeded (P < 0.05) respective 
responses to PPDb (Fig. S2). Using intracellular cytokine staining, IFN-γ responses to PPDb 
and to rESAT-6:CFP10 were also detected in long-term PBMC cultures at 3, 6, 8, and 12 wks 
after aerosol infection (Fig. 1C). Responses increased (P < 0.05) from 3 and 6 to 12 wks after 
infection. These findings demonstrate that infection of cattle with virulent M. bovis elicits long-
term cultured IFN-γ ELISPOT responses, which are considered a surrogate of Tcm responses 
in humans [34,38,45]. 
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Figure 1 Long-term cultured and ex vivo IFN- γ responses by cattle after M. 
bovis aerosol challenge. Cultured ELISPOT analysis was performed ~3 weeks 
after challenge with virulent M. bovis. Long-term cultured cells were generated 
by stimulating PBMC with a cocktail of rAg85A (1 µg/ml), rTB10.4 (1 µg/ml), 
and rESAT-6:CFP10 (1 µg/ml) antigens as well as PPDb (5 µg/ml) for 13 days 
followed by transfer to ELISPOT plates with APCs and addition of either 
rESAT-6:CFP10, PPDb or medium alone. For the ex vivo response, freshly 
isolated PBMCs were stimulated with rESAT-6:CFP10, PPDb or medium alone 
for 16h. Medium control responses were subtracted from antigen-stimulated 
responses and results are presented as mean spot forming cells (SFC)/million 
cells (± SEM, n = 8) for (A) long-term culture or (B) ex vivo conditions. (C) 
The kinetics of the response is shown as the percent of CD4+ cells producing 
IFN-γ in long-term cultures at 3, 6, 8, and 12 weeks post infection (WPI n = 6). 
Two-way ANOVA (Šídák’s multiple comparison post-test).  
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Analysis of IFN-γ production in long-term cultures reveals a dominant contribution by 
Tcm  
The expression of CD45RO, CD4, CCR7 and intracellular expression of IFN-γ by 
PBMC cells was evaluated following long-term or ex vivo culture (Fig. 2). CD4 T cells 
producing IFN-γ following long-term culture predominantly co-expressed CD45RO and CCR7 
surface antigens (Fig. 3), consistent with the Tcm phenotype described for humans and mice 
(Fig. S3) [26],[46]. The phenotype of cells responding to PPDb (CD4+ IFN-γ+) was compared 
under ex vivo versus long-term culture conditions (Fig. 3A and S4A). The predominant cell 
phenotype responding to antigenic stimulation in long-term cultures was that of Tcm cells, 
whereas few Tcm were present under ex vivo conditions (P < 0.01, % Tcm in long-term versus 
ex vivo cultures). In contrast, effector cells contributed to ex vivo IFN-γ production, but only 
minimally to the long-term culture response (P < 0.05). Tem cells contributed to IFN-γ 
production in both ex vivo (~50%) and long-term cultures (~25%). The respective overall 
effector/memory CD4 T cells (i.e. CD4+ IFN-γ+/- cells) proportions under both long- and short-
term conditions are shown in Fig. S4B. The relative contribution of Tcm, Tem and effector 
CD4+ T cells in the response to PPDb (Fig. 3B) and to rESAT-6:CFP10 (Fig. 3C) remained the 
same over the course of infection (i.e., at 6, 8, and 12 wks after challenge). In general a greater 
number of responding cells (IFN-γ+) were observed in the long-term cultured assay as 
compared to the ex vivo assay (Fig. 3), perhaps due to the greater percentage of CD4 cells 
within long-term cultures (Fig. S5). 
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Figure 2 Representative gating strategy for evaluation of CD45RO and CCR7 expression 
on CD4 T cells producing IFN-γ. Approximately 8 weeks after aerosol challenge with M. 
bovis, long-term cultures were generated by stimulating PBMC with a cocktail of rAg85A (1 
µg/ml), rTB10.4 (1 µg/ml) and rESAT-6:CFP10 (1 µg/ml) as well as PPDb (5 µg/ml) for 13 
days followed by transfer of cells to ELISPOT plates with APCs and restimulation with PPDb. 
Gating hierarchy (gating sequence as depicted by the arrows): (A) Single cells (within the 
oblong gate), (B) Lymphocytes (within the polygon gate), (C) CD4+ cells, (D) CD4+ cells 
producing IFN-γ, and (E) CD45RO and CCR7 expression for determination of 
effector/memory phenotypes.  
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Figure 3 Frequencies of Tcm, Tem and effector cells producing IFN-γ in response to 
mycobacterial antigens in long-term and ex vivo assays. Peripheral blood mononuclear cells 
were isolated from calves ~ 8 weeks after challenge with virulent M. bovis. Cells were 
stimulated with a cocktail of rAg85A (1 µg/ml), rTB10.4 (1 µg/ml), and rESAT-6:CFP10 (1 
µg/ml) as well as PPDb (5 µg/ml) for 13 days followed by transfer to 96 well round bottom 
plates with APCs and addition of media alone, PPDb or rESAT-6:CFP10 for an additional 16h. 
For ex vivo culture, PBMC were stimulated with media alone, PPDb or rESAT-6:CFP10 for 
16h. (A) Relative contribution of Tcm, Tem, and T effector cells to IFN-γ production in 
response to PPDb by long-term (i.e., 14-day) (left) and ex vivo (i.e., 16 hr) (right) cultures, 8 
weeks after M. bovis challenge. Data are presented in percentages (pies) and as mean (± SEM) 
number of cells producing IFN-γ / 104 cells (histograms) (n=16). Relative contribution of Tcm, 
Tem and T effector cells to IFN-γ production in response to PPDb (B) or to rESAT-6:CFP10 
(C) in long-term cultures at three, six, eight or 12 weeks post-infection (WPI, n=6). Tcm, Tem 
and effector cell phenotypes were as defined in Fig. 2 and Fig. S3. Tcm and Effector T cell 
contribution to IFN-γ production differs (*P < 0.05; **P < 0.01, paired Student's t-tests) 
between short- and long-term cultures.  
 
Tcm cells highly expressed (P < 0.05) CD62L and CD44 in response to either rESAT-
6:CFP10 or PPDb stimulation (Fig. 4). Expression of CD62L was intermediate with Tem and 
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low to non-existent with effector cells (Fig. 4A). CD44 expression was low in both Tem and 
effector cells (Fig. 4B).  
 
Figure 4 CD62L and CD44 expression by Tcm, Tem and effector CD4+ cells in long-term 
(14 day) cultures. Analysis of long-term cultured PBMCs was performed ~ 8 weeks after 
aerosol challenge with virulent M. bovis. Cells were stimulated with a cocktail of rAg85A (1 
µg/ml), rTB10.4 (1 µg/ml), and rESAT-6:CFP10 (1 µg/ml), as well as PPDb (5 µg/ml) for 13 
days followed by transfer to 96 well round bottom plates with APCs and addition of PPDb or 
rESAT-6:CFP10. Data are presented as mean fluorescence intensity (MFI, y-axis, ± SEM) of 
CD62L or CD44 by CD4+ cells of the various effector / memory subsets (x-axis). (A) CD62L 
expression by Tcm, Tem and effector cells in response to PPDb and rESAT-6:CFP10. (B) 
CD44 expression on Tcm, Tem and effector cells in response to PPDb and rESAT-6:CFP10. 
Tcm, Tem and effector cell phenotypes were as defined in Fig. 2 and Fig. S3. Paired Student's 
t-tests (n=8). 
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Tcm cells possess high proliferative capability 
Human CD4 memory T cells, predominantly those exhibiting Tcm phenotype, 
proliferate in response to cytokine and antigenic stimulations, differentiating into Tem or 
effector T cells in vitro [30,47]. To assess the proliferative capacity of bovine Tcm cells 
following long-term culture, cells were harvested at day 13 and stained with CellTrace Violet. 
CellTrace Violet stained cells were re-stimulated with rESAT-6:CFP10 or PPDb for additional 
six days, without IL-2 (Fig. S5). For comparative purposes, freshly isolated PBMC were 
isolated and stained with CellTrace Violet and cultured for six days (short-term culture). Cells 
proliferated in response to antigenic stimulation under both long- and short-term conditions 
(Table 2). CD4 T cells were the most proliferative fraction (P < 0.05), followed by γδ, CD8 T 
cells, and CD8 expressing γδ T cells. In response to rESAT-6:CFP10 stimulation, the number 
of CD4 T cells proliferating in long-term cultures exceeded (P < 0.05) that of short-term 
cultures. Similarly, the CellTrace Violet mean fluorescence intensity (MFI) was significantly 
lower (P = 0.003), indicating greater cell proliferation in rESAT-6:CFP10-stimulated CD4 T 
cells in long- vs short-term cultures (Fig. 5 and Fig. 6). Greater percentages of CD4 T cells (P 
< 0.05) proliferated under long-term culture in response to either rESAT-6:CFP10 (Fig. 6A) or 
PPDb (Fig. 6B). These findings demonstrate that bovine Tcm cells are highly proliferative in 
response to repeated stimulation with recall antigen. 
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Table 2 Lymphocyte subset proliferative responses of M. bovis-infected cattle under short or 
long-term culture condition 
 
 
Figure 5 Proliferation of cell subsets in response to mycobacterial antigens. Approximately 
7 weeks after M. bovis challenge, PBMCs from infected cattle were either long or short-term 
cultured (6 days). Long-term cells consisted of PBMCs cultured in the presence of rAg85A, 
rTB10.4, rESAT-6:CFP10 and PPDb for 13 days (n = 4). Subsequently, cells were stained with 
CellTrace violet dye and re-stimulated with either rESAT-6:CFP10 or medium in the presence 
of APCs for an additional six days. Short-term cells consist of CellTrace Violet-stained PBMC 
from M. bovis-infected cattle cultured for six days in the presence of either rESAT-6:CFP10 or 
medium (n=4). Proliferative responses of cells under both culture conditions were compared 
for each T cell subset. Data are presented as mean fluorescence intensity (MFI, y-axis) of 
CellTrace Violet for analysis of proliferation of T cell subsets (x-axis). Two-way ANOVA, 
n=6, Šídák’s multiple comparison post-test. 
 	
80	
Given the robust participation of CD4 T cells in the long-term proliferative response 
and the fact that Tcm cells are believed to generate effector cells, the phenotype of these cells 
(i.e., 14-day cultured cells re-stimulated with antigen for an additional 6 days) was further 
assessed. Again, PBMCs cultured under short-term culture conditions (6 days only) were used 
for comparison (Fig. 6). The distribution of CD4 T cells into Tcm and effector subsets was 
different between short- and long-term conditions following stimulation with rESAT-6:CFP10 
(Fig. 6C) or PPDb (Fig. 6D). Greater (P < 0.05) numbers of Tcm cells were present in long-
term (13 + 6 days) versus short-term (6 days) cultures; while more effector cells were present 
(P < 0.05) in short– versus long-term cultures. The numbers of Tem and naïve cells were 
similar between the two conditions. Tem cells were the main population in both cultures, 
whereas few naïve cells persisted under either culture condition (Fig. 6C and D). These 
findings indicate that highly proliferative Tcm cells partially revert to effector (predominantly 
Tem) phenotypes upon additional exposure to antigen for 6 days (Fig. 6C and D as compared 
to Fig. 3). 
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Figure 6 Long-term cultured cells have higher proliferative responses than short-term 
cells. Long-term and short-term cultured PBMCs were analyzed ~ 7 weeks after aerosol 
challenge with virulent M. bovis. Long-term cells consist of PBMC from M. bovis aerosol 
infected cattle cultured in the presence of rAg85A, rTB10.4, rESAT-6:CFP10 and PPDb for 13 
days and then CellTrace violet-stained and re-stimulated with either rESAT-6:CFP10, PPDb or 
medium in the presence of fresh autologous adherent cells for an additional six days. Short-
term cells consist of CellTrace violet-stained PBMC from M. bovis aerosol infected cattle 
cultured for six days in the presence of either rESAT-6:CFP10, PPDb or medium. The gating 
strategy was performed in accordance with procedures described in Figure 2A for single cells, 
and as shown in Figure S3 for lymphocytes, and CD4+ cells. (A) Percentages of CD4+ cells 
proliferating (low Celltrace dye MFI) in response to rESAT-6:CFP10 within long or short-term 
cultures. (B) Percentages of CD4+ cells proliferating (low Celltrace dye MFI) in response to 
PPDb within long or short-term cultures. (C) Memory/effector phenotype of proliferating 
CD4+cells within long-term or short-term cultures in response to rESAT-6:CFP10. (D) 
Memory/effector phenotype of proliferating CD4+cells within long-term or short-term cultures 
in response to PPDb. For panels A and B, cell proliferation differs (**P < 0.01, n=6 paired 
Student's t-tests) between long and short-term cultures to either rESAT-6:CFP10 or PPDb. For 
panels C and D, Tcm and effector cell content differs (*P < 0.05; **P < 0.01, n=4 paired 
Student's t-tests) between short-term and long-term cultures to either rESAT-6:CFP10 or 
PPDb. 
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Discussion  
 
This study characterizes Tcm cells in cattle and their participation in the immune 
response to M. bovis infection. As early as 6 weeks after M. bovis infection, CD4+ Tcm cells 
(CD45RO+, CCR7+) were detected in long-term, antigen-stimulated PBMC cultures upon 
recall stimulation with specific (i.e., rESAT-6:CFP-10) or complex (i.e., PPDb) antigens of M. 
bovis (Fig. 3). Antigen-specific CD4 cells, as detected by IFN-γ production via either 
ELISPOT (Fig. 1A and B) or intracellular cytokine staining (Fig. 1C, 2 and 3), within long-
term PBMC cultures were predominantly (~76%) Tcm cells (CD45RO+ / CCR7+), with the 
remainder being Tem cells (CD45RO+ / CCR7-, ~23%) (Fig. 3). Bovine Tcm were highly 
proliferative as antigen restimulation of cells within long-term cultures induced robust 
proliferation of CD4+ cells that significantly exceeded that of short-term culture cells (Table 2, 
Fig. 5, 6A and S5). Further phenotypic analyses of repeat stimulated cultures indicated that a 
sub-population of bovine Tcm reverted to effector (both Tem and T effector) phenotypes upon 
repeat exposure to M. bovis antigens (Fig. 6B). The identification and characterization of CD4 
Tcm and Tem subpopulations in cattle should prove useful for development of vaccines and 
the understanding of the immunopathogenesis for many infectious diseases of cattle.  
Memory cells elicited either by vaccination [30,48] or during pathogen clearance 
[15,32] are thought to provide long-term protection due to their prolonged life-span, 
proliferation potential, and plasticity [7,33,48]. While events governing immunological 
memory during chronic infections (wherein the antigenic stimulation persists) are not well 
understood, a significant Tcm response is associated with a favorable outcome for chronic 
infections, such as HIV and TB (e.g., latency and self-healing with TB and subclinical disease 
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with HIV) [31,38]. Still, the relative importance of Tcm for protective immunity against TB is 
not fully established. Tcm and ex vivo responses are detected in M. tb-infected patients [33,37] 
and loss of Tcm responses (as measured by cultured IFN-γ ELISPOT) is associated with 
clinical disease progression [27,37]. Likewise, Tcm responses in the absence of ex vivo IFN-γ 
production indicates disease remission, either by self-healing [34,38] or anti-mycobacterial 
therapy, reinforcing the role that pathogen clearance has on Tcm function and/or maintenance 
[34,37]. Intriguingly, in spite of the presence of Tcm cells, patients receiving curative treatment 
are still susceptible to M. tb re-infection [28,31,49]. In the current set of experiments, each of 
the calves had mild progressive disease and were responsive to TB antigens in both cultured 
and ex vivo IFN-γ ELISPOT assays - similar to what occurs in humans with the mild active 
form of M. tb infection [38]. Flow cytometric analysis demonstrated that both Tem and Tcm 
cells were elicited relatively early after infection (3 weeks post-infection, Fig.1). It is uncertain 
if Tcm responses by the animals would decrease as the disease progresses, but it is frequently 
reported that animals in late stages of infection become anergic to measures of cell-mediated 
immunity, yielding false negative results upon skin test or ex vivo IFN-γ assays [50-52]. 
Prolonged infection trials with cattle are difficult due to biocontainment costs and ethical issues 
associated with extended duration of housing large animals within restrictive facilities. Thus, 
further studies to characterize the progression of Tcm responses to M. bovis infection in cattle 
may require sampling of field reactors with various clinical manifestations of the disease 
including: chronic progressive disease, M. bovis detected yet no visible lesions (i.e., analogous 
to latency in humans), and severe disseminated disease. 
Although IFN-γ is key to a successful containment of mycobacterial infections, the 
interaction between pathogens and host is intricate. Several factors and cytokines may be 
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relevant to M. bovis infection outcome. Together with IFN-γ, tumor necrosis factor alpha 
(TNF-α) is crucial for the control of mycobacterial infections of humans and mice [53]. Also, T 
cells producing multiple cytokines have been recently identified and may play an important 
role in infection outcome. Polyfunctional T cells co-producing IFN-γ, TNF-α and IL-2 are 
associated with infection control in HIV, hepatitis C, leishmaniasis and malaria (reviewed in 
[54,55]). With TB, conflicting data indicate that polyfunctional T cell responses are associated 
with either clinical disease (i.e., as a biomarker of active TB) or infection control [55]. 
Polyfunctional T cells were also recently described in cattle in the response to M. bovis 
infection [56] and to anti-mycobacterial vaccines [57]. Studies on polyfunctional responses of 
bovine memory T cells under our system (long-term cultured cells) are currently in progress. 
Additionally, TNF-α and IL-2 have been evaluated in cattle for diagnostic purposes [58,59]. 
Upon M. tb infection, the primary immune response may take days to weeks to develop 
relying on exposure of naive T cells to antigens in secondary lymphoid organs, expansion of 
antigen-specific cells, and homing of effector cells to the site of infection [60]. With TB, this 
2–3 week delay in the response at the primary site of infection seems to be advantageous for 
the bacteria, and is observed during infection in cattle, humans, and mice [61]. In theory, the 
delay allows the pathogen an opportunity to establish a niche and to direct the ensuing immune 
response in favor of bacterial persistence and chronic immune stimulation. A more rapid 
homing of antigen-specific cells to the site of infection (e.g., as may occur in vaccinated 
animals) might be advantageous to the host, allowing more effective induction of immune 
responses (e.g., different activation status, cytokine profile) and circumvention of the 
pathogens regulation of host immunity [14,62,63]. These factors may partially explain why 
Tcm responses elicited by vaccination appear to be beneficial to the host, while similar Tcm 
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responses are detected in infected animals with progressive disease. The presence of a robust 
TB-specific Tcm population elicited by vaccination prior to infection may lead to pathogen 
clearance before establishment of immune evasion tactics by the pathogen. Present findings 
provide a basis for future studies to determine the relative role of these Tcm and Tem subsets 
in vaccine-elicited protection. 
Lymphocyte homing and trafficking to sites of inflammation and lymphoid organs are 
mediated by the expression of numerous surface adhesion molecules, such as CCR7, CD62L 
and CD44. CD62L mediates cell adhesion to peripheral lymph node vascular addressins (e.g., 
GlyCAM-1 and MAdCAM-1) [64]. The expression of CD62L on naïve and memory T cells 
facilitates cell rolling on endothelium in secondary lymphatic organs, contributing to the 
compartmentalization of the immune response [64]. CD44 expression on T cells is up regulated 
upon activation, thereby promoting movement through the extracellular matrix via interactions 
with hyaluronic acid and fibronectin [65]. In vitro stimulation of antigen specific T cells is 
known to up-regulate CD44 while concurrently down regulating CD62L expression in humans 
[66], mice [67] and cattle [56,68]. As in humans [66], bovine T cells expressing CD44 upon ex 
vivo stimulation frequently co-express CD45RO, while down regulating CD62L [56,68]. In the 
present study, CD44 expression on CD4 cells did not differ between Tem and effector cells 
under ex vivo or long-term culture conditions (Fig. 4B). It is noteworthy that in the present 
study the expression of CD62L and CD44 was evaluated only among IFN-γ producing cells; 
thus, comparisons between resting/unstimulated versus responding/stimulated cells were not 
performed as previously described [68]. Also, the gating strategy employed (based on CCR7 
and CD45RO expression) may also have contributed to the apparently discrepant findings. In 
the present work, the expression of CD62L was down regulated in effector cells, intermediate 
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on Tem cells, and high on Tcm cells (Fig. 4A). Although Tcm cells highly expressed CD62L, 
these cells maintained high CD44 expression. The relevance of the level of CD44 expression 
by memory T cells is controversial for both mice [15,69,70] and humans [66,69]. Although few 
authors investigated T cell memory responses in cattle [24,26,41,71-73], to our knowledge no 
other description of the expression of CD44 by bovine Tcm cells (as defined by CCR7 and 
CD45RO expression) has been published, making direct comparisons not possible. However, 
data from mice suggest that although the expression of CD44 is dispensable for early 
expansion, trafficking and cytokine production of Th1 cells; expression of CD44 is required for 
long-term cell survival and anamnestic responses to re-infection [70]. In humans and mice it is 
long known that, together with CD62L, CCR7 plays a major role for cell homing to secondary 
lymphoid organs (SLO). For cattle, CCR7 expression is required for CD4 T cell migration to 
SLO, while homing of γδ T cells to SLO is not mediated by CCR7 expression [74]. To our 
knowledge further cytometric analysis of CCR7 positive cells into Tcm and naïve subsets, as 
well the antigen specific memory response to infection has not been done in cattle. Totté et al. 
[73] reported a subset of CD4 cells with Tcm characteristics after Mycoplasma mycoides 
infection and pathogen clearance. Upon restimulation, cells expressing CD62L were highly 
proliferative, while being less prone to down regulate CCR7 transcription. Conversely, cells 
lacking CD62L showed greater IFN-γ production, lower proliferation and down regulation of 
CCR7 transcription. Our findings indicate that in response to antigenic stimulation, Tcm cells 
strongly proliferated (Fig. 5 and 6A) and were capable of switching to Tem and effector cells 
(CCR7 down regulation - Fig. 6B).  
We also analyzed the contribution of γδ, CD8 and CD8-expressing γδ T cells to the 
proliferative response of long- and short-term cultures. In cattle, CD8+ T-cells can bear either 
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α/β or γ/δ TCR, with profound impacts on antigen specificity and immunological memory, as 
classical antigen-specific immunological memory resides in α/β T-cells [75,76]. In BCG 
vaccinated animals, CD8 memory responses were elicited within the CD8 α/β TCR expressing 
cells, but not the CD8 expressing γδ T cells [76]. In the present study, γδ- CD8+ T cells showed 
greater proliferation under short-term culture conditions, while the proliferative response of γδ+ 
CD8+ T cells did not differ based on culture length (i.e., short- vs long-term). However, 
γδ+CD8+ T cells constituted only a small population under both culture conditions (Table 1). 
In summary, the present study demonstrates Tcm cells in the response to experimental M. 
bovis challenge. Our findings suggest that upon repeat in vitro stimulation Tcm cells proliferate 
into different effector cell types. The association of Tcm cells with vaccine-elicited protection, 
as well as in infection outcome, is still to be determined. 
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Supplemental information 
 
 
S1 Fig. Cattle infected with either M. bovis 95–1315 or M. bovis 10–7428 have 
similar long-term cultured and ex vivo IFN-γ responses after M. bovis aerosol 
challenge. Cultured ELISPOT analysis was performed ~3 weeks after challenge with 
virulent M. bovis. Long-term cultured cells were generated by stimulating PBMC with 
a cocktail of rAg85A (1 µg/ml), rTB10.4 (1 µg/ml), and rESAT-6:CFP10 (1 µg/ml) 
antigens as well as PPDb (5 µg/ml) for 13 days followed by transfer to ELISPOT plates 
with APCs and addition of either rESAT-6:CFP10, PPDb or medium alone. For the ex 
vivo response freshly isolated PBMCs were stimulated with rESAT-6:CFP10, PPDb or 
medium alone for 16h. Medium control responses were subtracted from antigen-
stimulated responses and results are presented as mean spot forming cells (SFC)/million 
cells (± SEM, n = 8) for (A) long-term culture or (B) ex vivo conditions. Responses did 
not differ between M. bovis 95–1315 and M. bovis 10–7428 infection groups (Two-way 
ANOVA, followed by Tukey’s multiple comparison). 
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S2 Fig. Evaluation of IFN-γ responses to M. avium-derived PPD (PPDa) and M. bovis-
derived PPD (PPDb) before challenge. Responses to PPDa and PPDb prior to challenge 
were examined using a commercial IFN-γ release assay (i.e., Bovigam, Prionics Ag, 
Schlieren, Switzerland) according to manufacturer instructions. Briefly, duplicate 250l 
heparinised whole blood aliquots were distributed in 96-well plates with PPDb (10g/ml, 
Prionics Ag), PPDa (10g/ml, Prionics Ag), or no antigen and incubated at 39°C/5% CO2 
for 20 hours. IFN-γ concentrations in stimulated plasma were determined using a 
commercial ELISA-based kit (Bovigam, Prionics Ag). Absorbencies of standards 
(recombinant bovine IFN-γ; Endogen, Rockford, IL) and test samples were read at 450 nm 
using an ELISA plate reader (Molecular Devices, Menlo Park, CA). Duplicate samples for 
individual treatments were analyzed and data presented as optical densities at 450 nm of 
the response to PPDb or PPDa minus the response to no-antigen (mean ± SEM). *Response 
to PPDa exceeded (P < 0.05, n=24, paired Student's t-test) the response to PPDb. 
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S3 Fig. Effector/memory phenotype of cells producing IFN-γ in response to PPDb 
under long-term and ex vivo conditions by infection group (A) and the respective 
efector/memory distribution of total CD4 cells, both IFN-γ+ positive and IFN-γ- (B). 
Peripheral blood mononuclear cells were isolated from calves ~ 8 weeks after challenge 
with virulent M. bovis (n = 8). Cells were stimulated with a cocktail of rAg85A (1 
µg/ml), rTB10.4 (1 µg/ml), and rESAT-6:CFP10 (1 µg/ml) as well as PPDb (5 µg/ml) 
for 13 days followed by transfer to 96 well round bottom plates with APCs and addition 
of media alone, PPDb or rESAT-6:CFP10 for an additional 16h. For ex vivo culture, 
PBMC were stimulated with media alone, PPDb or rESAT-6:CFP10 for 16h. (A) 
Relative contribution of Tcm, Tem, and T effector cells to IFN-γ production in response 
to PPDb by long-term (i.e., 14-day) (left) and ex vivo (i.e., 16 h) (right) cultures did not 
differ between M. bovis 95–1315 (solid) or M. bovis 10–7428 (dashed) infection groups 
for any of the phenotypes (Two-way ANOVA, Šídák’s multiple comparison post-test). 
(B) Relative distribution of Tcm, Tem and T effector CD4+ cells in response to PPDb. 
(mean ± SEM, *P < 0.05, **P < 0.01; n = 8, Two-way ANOVA, Šídák’s multiple 
comparison post-test). 
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S4 Fig. Cell function and expression of cell markers on different human T cell 
memory subsets. (A) Identification of memory subsets in the human peripheral blood 
based on the expression of CD45R0, CCR7, CD62L in naïve, central memory T cells 
(Tcm), effector memory T cells (Tem) and effector T cells. (B) The differentiation of T 
cells occurs simultaneously with changes in cell functions. Adapted from Mahnkea et al. 
[46] 
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S5 Fig. Representative cytometric plots of the long-term and short-term cultured 
proliferative responses to mycobacterial antigens by CD4, CD8 and γδ T cells. 
Long-term and short-term cultured PBMCs were analyzed ~ 7 weeks after aerosol challenge 
with virulent M. bovis. Long-term cells consist of PBMC from M. bovis infected cattle cultured 
in the presence of rAg85A, rTB10.4, rESAT-6:CFP10 and PPDb for 13 days and then 
CellTrace violet-stained and re-stimulated with either rESAT-6:CFP10, PPDb or medium in 
the presence of fresh autologous adherent cells for an additional six days. Short-term cells 
consist of CellTrace violet-stained PBMC from M. bovis infected cattle cultured for six days in 
the presence of rESAT-6:CFP10, PPDb or medium. 
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Abstract 
Central memory T cells (Tcm’s) and polyfunctional CD4 T responses contribute to vaccine-
elicited protection to both human and bovine tuberculosis (TB); however, their combined role 
in protective immunity to TB is unclear. To address this question, we evaluated polyfunctional 
cytokine responses by CD4 T cell effector / memory populations from bacille Calmette Guerin 
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(BCG) vaccinated and non-vaccinated calves prior to and after aerosol challenge with virulent 
Mycobacterium bovis. Polyfunctional cytokine expression patterns in the response by Tcm’s, 
effector memory, and effector T cell subsets were similar between BCG-vaccinated and M. 
bovis-infected calves, only differing in magnitude (i.e., infected > vaccinated). BCG 
vaccination, however, did alter the kinetics of the ensuing response to virulent M. bovis 
infection. Early after challenge (3 weeks post infection), non-vaccinates had greater antigen-
specific IFN-γ/TNF-α and lesser IFN-γ/TNF-α/IL-2 responses by Tcm’s than did vaccinated 
animals. Importantly, these differences were also associated with mycobacterial burden upon 
necropsy. Polyfunctional responses to ESAT-6:CFP10 (antigens not synthesized by BCG 
strains) were detected in memory subsets, as well as effector cells, as early as three weeks after 
challenge. These findings suggest that cell fate divergence through asymmetric division occurs 
early after antigen priming in the response to bovine TB and that memory and effector T cells 
may expand concurrently during the initial phase of the immune response. In summary, robust 
IFN-γ/TNF-α responses by Tcm’s are associated with greater mycobacterial burden while IFN-
γ/TNF-α/IL-2 responses by Tcm’s are indicative of a protective response to bovine TB. 
 
Introduction 
 
Bovine tuberculosis (TB) is a chronic bacterial infection affecting livestock, humans 
and wildlife 1. Mycobacterium bovis, a member of the Mycobacterium tuberculosis complex, is 
the primary agent of TB in cattle, which causes substantial economic hardship for livestock 
producers. It is estimated that 50 million cattle are infected worldwide, costing approximately 
$3 billion annually to the livestock industry. In Great Britain alone, over 300,000 cattle were 
slaughtered from 2003 – 2013 in an attempt to control the disease at a cost to taxpayers of £500 
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million 2. In addition to the socioeconomic ramifications of the disease, M. bovis poses a 
significant public health threat. The World Health Organization classifies bovine TB as one of 
the seven most neglected zoonotic diseases and as such, the disease is particularly devastating 
in resource poor settings due to limited regulatory control, consumption of non-pasteurized 
milk / non-inspected meat, and co-morbidities affecting host susceptibility and disease severity 
3. In addition to both animal and public health significance, M. bovis infection in cattle is an 
excellent model for human TB as adaptive immune responses and the ensuing 
immunopathogenesis are remarkably similar to that of M. tuberculosis infection in humans. 
Indeed, studies in cattle have been essential for the development of control strategies 
applicable to humans such as the tuberculin skin test, interferon-γ (IFN-γ) release assays 
(IGRA), bacille Calmette Guerin (BCG) vaccination, and approaches to differentiate infected 
from vaccinated individuals/animals (DIVA) (reviewed by 4). The study of human TB, 
including mouse and non-human primate models, has also led to considerable progress in the 
understanding and control of bovine TB. 
Immunological memory is a primary feature of adaptive immunity and an essential goal 
of vaccination 5.In naïve hosts, effector and memory T cells are generated through 
developmental programing of naïve cells following an infection or antigen exposure. If 
infection is controlled, the vast majority of T cells generated during the expansion phase are 
eliminated and memory T cells remain, sometimes for a lifetime 6. Two major subsets of 
memory T cells (i.e., CD45RA-/CD45RO+) in humans and cattle are distinguishable based on 
expression of the lymphoid homing receptors CD62L and CCR7, reflecting important 
differences in function. Central memory T cells (Tcm) express CD62L and CCR7, are long-
lived and home to lymphoid tissues while effector memory T cells (Tem) lack CCR7 and 
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express minimal to no CD62L. Tem’s may remain blood associated or home to peripheral 
tissues, either circulating or remaining confined in splenic red pulp and hepatic sinusoids 6. In 
humans, Tcm’s exhibit elevated interleukin 2 (IL-2) production and proliferation potential, are 
long-lived, and able to generate heterogenic progeny capable of both terminal differentiation 
and self-renewal 7. Tem’s are higher producers of effector molecules, such as IFN-γ, but 
exhibit low proliferation capability 6, 8, 9. In cattle, CD45RO+ CCR7+ memory cells in long-
term cultures express high levels of CD62L (secondary lymphoid tissue homing receptor) and 
CD44 (homing cell adhesion molecule) and exhibit greater proliferation potential as compared 
to CD45RO+ CCR7- memory cells 10. While bovine CD45RO+ CCR7+ CD62Lhi memory cells 
(Tcm’s) are elicited by M. bovis infection, their role in the response to protective BCG 
vaccination has not been evaluated. However, long-term cultured IFN-γ ELISPOT assays (so 
called, cultured IFN-γ ELISPOT) may be used as a surrogate of Tcm responses 8, 10-13. In cattle, 
cultured IFN-γ ELISPOT (i.e., 10-14 day culture followed by overnight recall stimulation) 
responses to BCG +/- subunit vaccines positively predict vaccine efficacy and duration of 
vaccine-induced protection 14-17. As with BCG vaccination of humans, protection provided by 
BCG in cattle varies widely 18-19. In humans, cultured IFN-γ ELISPOT responses are detected 
in spontaneously cured TB subjects in the absence of ex vivo responses (i.e., overnight recall 
stimulation) 20. In contrast to the cultured IFN-γ ELISPOT, ex vivo assays detect primarily 
effector and Tem responses as a result of the brief stimulation period (i.e., 16 to 24 h) and rapid 
cytokine production 21-23. 
Polyfunctional T cells simultaneously produce two or more cytokines with IFN-γ, IL-2, 
and tumor necrosis factor-α (TNF-α) being the most commonly measured 24, 25. Associations 
between protection and vaccination-induced polyfunctional T cells have been mainly studied in 
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small animal models 26, 29. In humans, strong polyfunctional responses are detected in M. 
tuberculosis-infected individuals and are generally a sign of disease progression. Still, high IL-
2 production is associated with a positive clinical status (e.g., latent or treated disease), while a 
strong IFN-γ/TNF-α response is associated with a failed response (i.e., active TB) 30. Human 
polyfunctional responses to vaccination both prior to TB exposure and in previously exposed 
individuals (i.e., latent infection) are extremely variable, much like BCG vaccination efficacy, 
and conflicting findings are reported30. Furthermore, the relative lack of efficacious TB 
vaccines for humans hinder the clear assessment of correlates of protection, including that of 
polyfunctional T cells 26, 27, 31-33. In cattle, T cell polyfunctionality has only been measured 
upon ex vivo recall stimulation 21, 36. These studies found no association between 
polyfunctional responses measured before challenge and vaccine success. However, 
polyfunctional responses to infection were associated with increased pathology and poor 
disease outcome 36. Polyfunctional responses by long-term cultured cells for enrichment of 
Tcm responses have not been evaluated in spite of the fact that cultured IFN-γ ELISPOT is one 
of the most promising protection correlates in cattle 14-17. Likewise, the discrimination of cell 
phenotype involved in cytokine production under both cultured and ex vivo conditions may be 
necessary to identify specific correlates of vaccine efficacy, useful for the prioritization of 
vaccine candidates for costly biosafety level 3 (BSL-3) efficacy trials. 
Early secretory antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10) are 
co-secreted proteins encoded by the RD-1 region of M. tuberculosis complex mycobacteria. 
Loss of the RD-1 region is the primary attenuating defect of BCG and this region is absent in 
non-tuberculous mycobacterial (NTM) species 37-40. The differential expression of ESAT-
6:CFP10 by tuberculous mycobacteria and their robust immunogenicity enables use of these 
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antigens as a tool to discriminate M. bovis-infected from NTM-exposed or BCG-vaccinated 
animals 41-45. Antigen 85A (Ag85A) and protein TB10.4 are immunodominant antigens present 
in M. tuberculosis complex mycobacteria and BCG strains 1. M. bovis purified protein 
derivative (PPD) is a complex antigenic formulation, including many antigens also found in 
NTM. In the present study, the use of these antigens permitted assessment of both broad (PPD) 
and specific (TB10.4, Ag 85A) responses to vaccination and infection, and exclusively to 
infection (ESAT-6:CFP10) 1. 
Vaccine preparations included in the present study were BCG Danish (Statens Serum 
Institut, Copenhagen, Denmark, Strain 1331) and a cocktail of four BCG Danish (Strain 1331) 
deletion strains including BCG ∆fdrA, BCG ∆leuCD ∆pks16, BCG ∆metA, BCG ∆mmaA4. 
BCG Danish is a widely used human pediatric vaccine to reduce human tuberculosis. Likewise, 
BCG Danish has been shown to reduce bovine TB disease burden in both experimental and 
field studies and has a well-established safety profile in cattle 1, 46-47. The BCG Danish deletion 
derivatives used in this study are more attenuated and safer than the parental BCG strain in 
immunocompromised mice 48,49 (and L. Berney-Meyer, M. Larsen, and W. R. Jacobs, 
unpublished data). In immunocompetent mice, the BCG deletions ∆fdr8, ∆mmaA4, and ∆pks16 
each result in enhanced mycobacterial immunogenicity through enhanced cross-presentation of 
mycobacterial antigens (∆fdr8), cytokine modulation (∆mmaA4), and biofilm formation 
(∆pks16) as compared to the parental BCG 48 (and L. Berney-Meyer, M.H. Larsen, and W.R. 
Jacobs, unpublished data). BCG mutants, such as these, may also be used as vaccine vectors to 
promote epitope-specific responses (e.g., BCG ∆pks12 for enhanced CD8 responses) 50. In the 
present study and as presented elsewhere 51, BCG Danish and the cocktail of BCG Danish 
deletions (hereafter called BCG mutants) were equally protective and induced similar IFN-γ 
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and Th17-associated cytokine responses, as evaluated in ex vivo assays for diagnostic purposes.  
A better understanding of the cattle immune system may be beneficial to the 
understanding of both human and bovine TB, and aid in the development of improved vaccine 
strategies in both species. Here, we investigated cytokine production (i.e., all combinations of 
IFN-γ, TNF-α, and IL-2) by flow cytometric analysis of memory T cells subsets in response to 
BCG vaccination and subsequent challenge with virulent M. bovis to determine how the 
elicited immune response correlated with infection outcome. Our findings indicate that early 
after infection, robust IFN-γ/TNF-α responses by Tcm’s are associated with greater 
mycobacterial burden while IFN-γ/TNF-α/IL-2 responses by Tcm’s are indicative of a 
protective response. 
 
Materials and Methods 
Animal Use Ethics and Biosafety 
All studies were approved by the National Animal Disease Center Animal Care and Use and 
Institutional Biosafety committees and performed under appropriate project licenses within the 
conditions of the Animal Welfare Act. All animals were housed in appropriate biological 
containment facilities at the National Animal Disease Center. Given the low dose challenge 
and relatively short duration of the studies, animals did not develop clinical signs of bovine TB 
necessitating palliative therapy such as cough, dyspnea, anorexia or weight loss. Strict 
biosafety protocols were followed to protect personnel from exposure to M. bovis throughout 
the study, including BSL-3 containment upon initiation of M. bovis challenge in animal rooms 
and standard BSL-3 laboratory practices for handling M. bovis cultures and samples from M. 
bovis-infected animals. 
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Mycobacterium bovis vaccination and challenge procedures 
Holstein steers were obtained from bovine TB-free herds in Iowa, USA and housed in a 
biosafety level-3 facility at the National Animal Disease Center, Ames, IA. For the first 
experiment (study 1), animals were experimentally infected with 104 colony-forming units 
(cfu) of M. bovis 10-7428 (n = 8) by aerosol inoculation as described by 52. For the second 
study (study 2), calves were randomly assigned to the treatment groups: no vaccination (n = 
10), vaccination with M. bovis BCG-Danish (Strain 1331; n = 9), vaccination with a cocktail of 
four BCG Danish deletion strains including BCG ∆fdr8, BCG ∆leuCD ∆pks16, BCG ∆mmaA4 
(Dao et al. 2008), and BCG ∆metA (Berney et al. 2015) (n =10). Vaccines (106 CFU, total 
dose) were administered subcutaneously at 2 weeks of age. Animals received M. bovis 10-7428 
by aerosol (5 x 102 cfu) at 3.5 months of age (i.e., 3 months after vaccination) as described by 
52. 
Mycobacterial isolation and assessment of lesions 
All calves were euthanized ~3.5 months after challenge with virulent M. bovis by intravenous 
administration of sodium pentobarbital. Tissues were examined for gross lesions and processed 
for microscopic analysis and isolation of M. bovis. Tissues collected included: lung; liver; 
mandibular, parotid, medial retropharyngeal, mediastinal, tracheobronchial, hepatic, and 
mesenteric lymph nodes. Lymph nodes were sectioned at 0.5 cm intervals and examined. Each 
lung lobe was sectioned at 0.5 – 1.0 cm intervals and examined separately. Lungs and lymph 
nodes (mediastinal and tracheobronchial) were evaluated using a semi-quantitative gross 
pathology scoring system adapted from Vordermeier et al. 53. Tissues collected for microscopic 
analysis were fixed by immersion in 10% neutral buffered formalin. For microscopic 
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examination, formalin-fixed tissues were processed by standard paraffin-embedment 
techniques, cut in 5 mm sections and stained with hematoxylin and eosin. Adjacent sections 
from samples containing caseonecrotic granulomata suggestive of bovine TB were stained by 
the Ziehl-Neelsen technique for identification of acid-fast bacteria. Microscopic tuberculous 
lesions were staged (I-IV) based on a scoring system developed by Wangoo et al. 54. 
 
Long-term and ex vivo cell culture 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coat fractions of blood 
collected in 2× acid-citrate-dextrose solution by density gradient centrifugation using ficoll-
paque (Sigma, St. Louis, MO). Complete RPMI medium for PBMC cell culture was RPMI 
1640 (GIBCO, Grand Island) supplemented with 2 mM L-glutamine, 25 mM HEPES buffer, 
100 units/ml penicillin, 0.1 mg/ml streptomycin, 1% non-essential amino acids (Sigma), 2% 
essential amino acids (Sigma), 1% sodium pyruvate (Sigma), 50 mM 2-mercaptoethanol 
(Sigma), and 10% (v/v) fetal bovine sera (FBS). Long-term cell cultures were generated by 
stimulating 2 × 106/ml PBMC with a cocktail of M. bovis PPD (PPD, 5 µg/ml, Prionics Ag, 
Sclieren, Switzerland) Antigen85A (Ag85A - 1 µg/ml, LIONEX Diagnostics and Therapeutics 
GmbH, Braunschweig, Germany), TB10.4 (1 µg/ml, LIONEX Diagnostics and Therapeutics 
GmbH), and/or ESAT-6/CFP-10 (1 µg/ml, kind gift from Chris Minion, Iowa State University) 
in complete RPMI medium. Cells were cultured (2 × 106cells/well, 1ml/well) in 24 well flat-
bottom microtiter plates (Nunc, Thermo Fisher, Waltham, MA) at 39°C/5% CO2 for 13 days. 
The normal body temperature of cattle (Bos taurus) is 39oC and incubation of human blood at 
39oC, as compared to 37oC, augments cytokine responses 55. Complete media containing 
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human rIL-2 (Sigma, 10 U/ml) was used to replace media from the PBMC cultures at days 3 
and 7. Fresh complete media without IL-2 was used at days 10 and 12.  
At day 13, cultured cells were plated (2 × 105 of cultured PBMC/well) into 96-well 
ELISPOT plates (Millipore, Watford, UK) and incubated in the presence of autologous APCs 
and either PPD (5 µg/ml), Ag85A/TB104 (1 µg/ml of each protein), ESAT-6:CFP10 (1 µg/ml), 
pokeweed mitogen (PWM, Sigma) (1µg/ml) or medium alone. Autologous APCs were isolated 
by adherence incubating 1 × 105 freshly isolated PBMC in complete medium at 39°C/5% CO2 
for 90 min in ELISPOT plates. Non-adherent cells were discarded and the adherent cells 
(APCs) washed four times with warm RPMI 1640 media. Fresh complete media containing 
antigen and long-term cultured cells were then incubated 20h at 39°C/5% CO2. Long-term 
cultured cells were then incubated 16h at 39°C/5% CO2 with Brefeldin A (Sigma, 10mg/ml) 
added at 4h of culture.  
For ex vivo culture, fresh PBMC isolated from buffy coat fractions of blood collected in 
2× acid-citrate-dextrose solution were plated into 96 well plates (2 × 105) and stimulated with 
either PPD (5 µg/ml), Ag85A/TB104 (1 µg/ml of each protein), ESAT-6:CFP10 (1 µg/ml), 
PWM (1µg/ml) or medium alone for 16h at 39°C/5% CO2 with Brefeldin A (Sigma, 10mg/ml) 
added at 4h of culture 56.  
 
Flow Cytometry  
Following the appropriate culture duration, cells were pooled from individual animal replicates 
according to in vitro treatments (i.e., stimulation). Cells were stained as described by Whelan 
et al. 21 for assessment of bovine polyfunctional CD4 T cells and Maggioli et al. 10 for 
assessment of bovine memory/effector CD4 T cell subsets with antibodies listed in Table 1. 
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Intracellular staining was performed following BD Perm/Wash instructions (BD Biosciences, 
San Jose, CA). Flow cytometric analysis was performed with a BD LSR flow cytometer (BD 
Biosciences). Data were analyzed using FlowJo X (Tree Star Inc., San Carlos, CA). A 
representative plot of the gating strategy is depicted in Fig. S1. 
 
Statistical analysis 
Data were analyzed using Analysis of Variance followed by Sidak’s or Tukey’s multiple 
comparison test or Student’s t test using GraphPAD Prism 6.0 (GraphPAD Software Inc., La 
Jolla, CA). 
 
Table 1 Primary and secondary monoclonal antibodies and staining reagents 
 
 
 
 
 
 
 
Reagent Specificity, Source Fluorophore, Source 
ILA11 
Bovine CD4, Washington State 
University PE-Cy7, SouthernBiotech 
ILA116 
Bovine CD45RO, Washington State 
University APC-Cy7, Life technologies 
7D12 Human CCR7 (CD197), BD Pharmingen 
AF 350, Life technologies  or 
SpectralRed, SouthernBiotech 
MCA1783-PE Bovine IFN-γ, AbD Serotec Not applicable 
MCA2334-FITC Bovine TNF-α, BD Pharmingen Not applicable 
AbD14386-DyLight649 Bovine IL-2, AbD Serotec Not applicable 
Live/Dead staining PacificBlue, Life Technologies Not applicable 
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Results 
 
M. bovis infection of cattle elicits specific polyfunctional cytokine production by CD4 T cells in 
long-term and ex vivo cultures  
Prior studies have demonstrated that M. bovis infection of cattle elicits polyfunctional CD4 T 
cell responses 21, 36; however, the relative contribution of effector, Tem and Tcm subsets has 
not been evaluated. In the present study, individual cytokine (i.e., IFN-γ, TNF-α and IL-2) 
production by infected animals (study 1) did not differ between ex vivo or long-term cultured 
cells in response to either PPD or ESAT-6:CFP10 stimulation; however, the phenotype of 
responding cells greatly differed (P < 0.05) between culture conditions (Fig. 1). In response to 
either PPD (Fig. 1C) or ESAT-6:CFP10 (Fig. 1D), Tcm’s (CD4+ CD45RO+ CCR7+) comprised 
~80% of cytokine producing cells in long-term cultures while Tem’s (CD4+ CD45RO+ CCR7-) 
comprised ~60% of cytokine producing cells in ex vivo cultures. Analysis of CD4 T cell 
polyfunctional profiles (i.e., all combinations of IFN-γ, TNF-α and IL-2) revealed frequent co-
production of multiple cytokines under both ex vivo and long-term culture conditions in 
response to either PPD or ESAT-6:CFP10 by M. bovis-infected cattle (Table 2). IFN-γ/TNF-α 
and IFN-γ/TNF-α/IL-2 co-production were the predominant (p < 0.05) polyfunctional cytokine 
profile, regardless of culture condition. Also, long-term and ex vivo polyfunctional responses to 
either PPD or ESAT-6:CFP10 were comparable (i.e., comparison between the same profile 
under either ex vivo or long-term culture; p > 0.05) for all seven possible cytokine profiles 
(Table 2).  
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Figure 1. Individual cytokines produced by different effector/memory phenotypes 
based upon culture conditions. For long-term cultures, PBMCs were isolated and 
stimulated with a cocktail of Ag85A, TB10.4, and ESAT-6:CFP10 as well as PPD for 13 
days followed by transfer to 96 well round bottom plates with APCs and addition of 
media alone, PPD or ESAT-6:CFP10 for an additional 16h. For ex vivo culture, PBMCs 
were stimulated with media alone, PPD or ESAT-6:CFP10 for 16 h. Results are 
presented as average and standard error for responses over the course of the study (n = 5 
animals, 3 time points). Frequency long-term (closed bars) and ex vivo (open bars) 
cultured CD4 T cells producing IFN-γ, TNF-α or IL-2 in response to PPD (A) or ESAT-
6:CFP10 (B). Phenotype of long-term (closed bars) and ex vivo (open bars) CD4 T cells 
producing any combination of IFN-γ, TNF-α or IL-2 in response to PPD (C) or ESAT-
6:CFP10 (D) based on CD45RO and CCR7 expression (Fig. S1).  
* Responses from PBMCs differ (P < 0.05, Sidak's) between long-term and ex vivo cultures. 
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Table 2 IFN-γ/TNF-α/IL-2 and IFN-γ/TNF-α are the predominant polyfunctional profile 
in response to M. bovis infection, as assessed by long-term and ex vivo assays. 
 
 
PPD ESAT6:CFP10 
 Long-term ex vivo Long-term ex vivo 
Cytokine profile* Average (SEM) Average (SEM) Average (SEM) Average (SEM) 
IFN-γ/TNF-α/IL-2 3.92 (0.55) a 4.03 (0.78) a 4.51 (0.64) a 3.79 (0.71) a 
IFN-γ/TNF-α 4.44 (0.51) a 4.69 (0.59) a 5.37 (0.59) a 4.32 (0.70) a 
IFN-γ/IL-2 1.31 (0.09) b 1.26 (0.22) b 1.01 (0.36) b 1.18 (0.24) b 
TNF-α/IL-2 2.02 (0.24) b 2.09 (0.24) b 1.39 (0.14) b 2.06 (0.30) b 
IFN-γ 1.15 (0.12) b 1.27 (0.35) b 0.86 (0.13) b 1.28 (0.41) b 
TNF-α 0.31 (0.05) b 1.08 (0.23) b 0.20 (0.06) b 1.15 (0.28) b 
IL-2 0.98 (0.36) b 1.83 (0.29) b 1.48 (0.35) b 1.79 (0.34) b 
* Data are presented as frequencies (%) of cytokine producing cells within long-term or ex vivo 
cultures.  
abc; Different letters represent differences (P < 0.05) in the frequency of profiles within each culture 
condition (long-term or ex vivo). Differences in polyfunctional profile frequencies between long-term 
and ex vivo were not detected (P > 0.05, Tukey's). 
 
 
As with the analysis of individual cytokine production, Tcm’s were the main phenotype 
contributing to polyfunctional responses in long-term cultures whereas Tem’s were the main 
subset producing cytokines in ex vivo cultures (Fig. 2).  
Vaccine efficacy. 
Three and half months after vaccination (study 2), animals received virulent M. bovis by 
aerosol. Vaccine efficacy was assessed upon necropsy at 4.5 months after challenge. BCG 
mutants and BCG-vaccinates had reduced bacterial load (Fig. 3A, P < 0.05) and gross 
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Figure 2. Polyfunctional profiles by effector/memory phenotypes differ based on culture 
conditions. For long-term culture, PBMCs were isolated and stimulated with a cocktail of 
Ag85A, TB10.4, and ESAT-6:CFP10 as well as PPD for 13 days followed by transfer to 96 
well round bottom plates with APCs and addition of media alone, PPD or ESAT-6:CFP10 for 
an additional 16h. For ex vivo culture, PBMC were stimulated with media alone, PPD or 
ESAT-6:CFP10 for 16h. Results are presented as average and standard error for responses over 
the course of the study (n = 30, 5 animals x 3 time points). Percentages of polyfunctional 
profiles in response to long-term stimulation with PPD (A) or ESAT-6:CFP10 (B) or ex vivo 
stimulation with PPD (C) or ESAT-6:CFP10 (D) split by effector/memory phenotype based on 
CD45RO and CCR7 expression (Fig. S1).  
* Responses differ (P < 0.05, Tukey's) from the other two phenotypes.  
abc Different letters represent differences (P < 0.05, Tukey's) in effector/memory phenotypes 
within a particular polyfunctional subset. 
 
pathology as compared to non-vaccinates (Fig. 3B, P < 0.05). Mean disease scores and M. 
bovis colonization did not differ between BCG mutants and BCG-vaccinates. Lesion staging by 
histology corroborated gross lesion results (Fig. 3C). Noteworthy, only non-vaccinated calves 
developed stage IV granulomas that generally contain large numbers of acid-fast bacilli 57, 
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likely associated with increased transmission. In summary, both vaccines were exquisitely 
protective, decreasing pathology and bacterial burden. 
 
 
Figure 3. BCG mutants and BCG vaccination confers protection against virulent M. bovis 
challenge. (A) Quantitative assessment of mycobacterial burden in tracheobronchial lymph 
nodes. (B) Total gross pathology scores from lung, tracheobronchial and mediastinal lymph 
nodes. (C) Data are presented as average number of stage I - IV microscopic lesions observed 
in mediastinal lymph nodes, tracheobronchial lymph nodes and lung based on the scoring 
system developed by Wangoo et al. 2005.  
* Parameters differ (P < 0.05, Tukey's) between non-vaccinates (n=10) and BCG mutants 
(n=10) or BCG vaccinates (n=9). 
 
Cytokine responses elicited by BCG vaccination. 
Vaccination of calves with either BCG or BCG mutants (study 2) elicited specific 
cytokine production at 6 weeks post-vaccination (WPV) in response to Ag85A/TB10.4 (Fig. 
4) and PPD (Fig. S2). As expected for this time point prior to M. bovis infection, non-
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vaccinated calves showed minimal or no responses to mycobacterial antigens. Long-term 
culture responses by vaccinated calves, as measured by IFN-γ, TNF-α and IL-2, were 
generally higher (P < 0.05) than the respective ex vivo responses (Fig. 4).  
 
Figure 4. Long-term and ex vivo cytokine responses to vaccination. For long-term culture, 
PBMCs were isolated at 6 WPV and stimulated with a cocktail of Ag85A, TB10.4, and PPD 
for 13 days followed by transfer to 96 well round bottom plates with APCs and addition of 
media alone or Ag85A/TB10.4 for an additional 16h. Results are presented as average and 
standard error. Frequency of long-term (left) and ex vivo (right) cultured CD4 T cells 
producing IFN-γ (A) TNF-α (B) and IL-2 (C). 
* abc; Different letters represent significant differences (P < 0.05) in cytokine production in 
long-term and ex vivo culture condition (Tukey's). 
 
As observed in infected calves (study 1), the proportion of Tcm, Tem and effector cells 
contributing to cytokine production differed between long-term and ex vivo cultures (Fig. 5, P 
< 0.05). Responding cells in long-term cultures most frequently exhibited a Tcm phenotype 
(Fig. 5A, P < 0.05), while ex vivo cytokine production was mainly due to Tem’s (Fig. 5B, P < 
0.05). Effector cells contributed to cytokine production by vaccinated animals under both 
culture conditions, but were more frequent in the ex vivo response (Fig. 5C, P < 0.05). The 
contribution of naïve cells to the cytokine response was minimal, and did not differ based on 
vaccination or culture conditions (Fig. 5D, P > 0.05). Cell phenotype (Tcm, Tem, and 
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effector) and polyfunctional profiles within long-term or ex vivo cultures did not differ 
between BCG mutants and BCG vaccinates to Ag85A/TB10.4 (Fig. S3) nor PPD (Fig. S4) at 
6 WPV.  
 
Figure 5. Vaccine elicited cytokine production is due to different effector/memory 
phenotypes based upon culture conditions. For long-term culture PBMCs were isolated at 6 
WPV and stimulated with a cocktail of Ag85A, TB10.4, and PPD for 13 days followed by 
transfer to 96 well round bottom plates with APCs and addition of media alone or 
Ag85A/TB10.4 for an additional 16h. Results are presented as average and standard error. 
Frequency of cytokine producing cells under long-term or ex vivo culture exhibiting Tcm (A), 
Tem (B), Effector (C) or Naïve (D) phenotype using the gating strategy described in Fig. S1.  
abc Different letters represent differences (P < 0.05) in cytokine production within memory 
subsets (i.e., Tcm, Tem, Effector or Naïve) in both long-term and ex vivo cultures (Tukey's). 
 
Vaccine-elicited polyfunctional responses were detected to PPD and Ag85A/TB10.4, 
but not to ESAT-6:CFP10 (Fig. 6). Thus, BCG vaccination elicits a specific polyfunctional 
CD4 T cell response and the culture duration (long-term vs ex vivo) dictates whether the 
response is primarily within Tcm or Tem subsets, respectively. These findings also confirm 
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that long-term cultured ELISPOT responses associated with protection to subsequent M. bovis 
infection in cattle are primarily a measure of CD4 Tcm responses14, 58. 
 
 
Figure 6. Specific Tcm responses to vaccination at 6weeks post vaccination. For long-term 
culture, PBMCs were isolated at 6 WPV and stimulated with a cocktail of Ag85A, TB10.4, and 
PPD for 13 days followed by transfer to 96 well round bottom plates with APCs and addition 
of media alone, PPD, Ag85A/TB10.4 or ESAT-6:CFP10 for an additional 16h. Results are 
presented as average and standard error. Polyfunctional responses by Tcm’s (gated on 
CD45RO+/CCR7+/CD4+ cells) were detected upon recall stimulation with PPD (A), 
Ag85A/TB10.4 (B), but not to ESAT-6:CFP10 (C).  
* Different (P < 0.05, Tukey’s) responses between non-vaccinates and both vaccinated groups. 
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Lower IFN-γ/TNF-α and higher IFN-γ/TNF-α/IL-2 co-production by Tcms early after infection 
by vaccinates as compared to non-vaccinates 
Early after challenge with virulent M. bovis (3 weeks post-infection - WPI), non-vaccinates had 
greater (P < 0.05) IFN-γ/TNF-α responses to PPD, Ag85A/TB10.4 and ESAT-6:CFP10 by 
Tcm’s than did vaccinated animals (Fig. 7). This difference was surprising given that 
vaccination elicited IFN-γ/TNF-α responses to PPD and Ag85A/TB10.4 and one might 
anticipate that these responses would be boosted after challenge with virulent M. bovis. In 
contrasted, the IFN-γ/TNF-α/IL-2 response by vaccinates exceeded (P < 0.05) the respective 
response by non-vaccinates early after challenge (Fig. 7). As with post vaccination responses, 
responses by BCG mutants and BCG vaccinates did not differ at 3 WPI (Fig. S5) and 8 WPI 
(data not shown). Also, polyfunctional responses by Tcm’s at 8 WPI were similar among 
vaccinates and non-vaccinates (Fig. 8). To investigate how vaccination and infection elicited 
responses contrast, we compared the polyfunctional cytokine response by vaccinates at 6 WPV 
to that of non-vaccinates at 3 WPI and 8 WPI. At 8 WPI, long-term and ex vivo responses to 
infection exceeded (P < 0.05) respective responses to vaccination for most polyfunctional 
profiles to both Ag85A/TB10.4 and PPD (Fig. S6). Importantly, both IFN-γ/TNF-α/IL-2 and 
IFN-γ/TNF-α responses to infection at 3 WPI (data not shown) and 8 WPI (Fig. S6) exceeded 
(P < 0.05) respective responses to vaccination upon recall stimulation of long-term cultures 
with Ag85A/TB10.4. Thus, both attenuated and virulent strains of M. bovis elicit 
polyfunctional T cell responses; however, these responses differ in magnitude.  
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Figure 7. Higher IFN-γ/TNF-α and lower IFN-γ/TNF-α/IL-2 Tcm responses by 
non-vaccinates versus vaccinates at 3 weeks post challenge. For long-term 
culture, PBMCs were isolated at 3 WPI and stimulated with a cocktail of Ag85A, 
TB10.4, and PPD for 13 days followed by transfer to 96 well round bottom plates 
with APCs and addition of media alone, PPD, Ag85A/TB10.4 or ESAT-6:CFP10 for 
an additional 16h. Results are presented as average and standard error. 
Polyfunctional responses by Tcm’s (gated on CD45RO+/CCR7+/CD4+ cells) were 
detected upon recall stimulation with PPD (A), Ag85A/TB10.4 (B) or ESAT-
6:CFP10 (C).  
* Parameters differ (P < 0.05, Tukey’s) in cytokine production by vaccinates versus 
non-vaccinates. 
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Figure 8. By 8 weeks post M. bovis challenge, polyfunctional responses by Tcm’s 
did not differ between vaccinates and non-vaccinates. For long-term culture, 
PBMCs were isolated at 8 WPI and stimulated with a cocktail of Ag85A, TB10.4, 
and PPD for 13 days followed by transfer to 96 well round bottom plates with APCs 
and addition of media alone, PPD, Ag85A/TB10.4 or ESAT-6:CFP10 for an 
additional 16h. Results are presented as average and standard error. Polyfunctional 
responses by Tcm’s (gated on CD45RO+/CCR7+/CD4+ cells) upon recall stimulation 
with PPD (A), Ag85A/TB10.4 (B) or ESAT-6:CFP10 (C).  
 
The most striking difference between vaccinates and non-vaccinates was the relative 
contribution of IFN-γ/TNF-α/IL-2 and TNF-α/IFN-γ production by Tcm’s early after challenge 
(3 WPI). The kinetics of long-term culture Tcm’s expressing these polyfunctional profiles is 
depicted in Fig. 9. Vaccination elicited IFN-γ/TNF-α/IL-2 and IFN-γ/TNF-α polyfunctional 
0
1
2
3
 BCG
Short-term Infected
0.0
0.5
1.0
1.5
2.0
M. Bovis BCG
Non-vaccinated 
0
1
2
3
4
Non- vaccinated 
M. Bovis BCG
Non-vaccinates 
Vaccinates 
A. PPD  
B. Ag85A/TB10.4 
C. ESAT-6:CFP10 
Non-vaccinates 
Vaccinates 
Non-vaccinates 
Vaccinates 
%
 P
PD
 
sp
ec
ifi
c 
C
D
4 
T 
ce
lls
  
 %
 E
SA
T-
6:
C
FP
10
 
sp
ec
ifi
c 
C
D
4 
T 
ce
lls
  
%
 A
g8
5a
 / 
TB
10
.4
  
sp
ec
ifi
c 
C
D
4 
T 
ce
lls
  
IFN-γ X X X X 
TNF-α X X X X 
IL-2 X X X X 
 	
122	
Tcm responses to Ag85A/TB10.4, but not to ESAT-6:CFP10. Three weeks after challenge, 
IFN-γ/TNF-α responses by Tcm’s were greater in non-vaccinates as compared to vaccinates 
(Fig. 9, P < 0.05), while vaccinates maintained higher percentages of IFN-γ/TNF-α/IL-2 
producing Tcm’s in comparison to non-vaccinates (Fig. 9, P < 0.05). At eight weeks post 
challenge, TNF-α/IFN-γ/IL-2 and TNF-α/IFN-γ responses were similar between vaccinates and 
non-vaccinates (Fig. 9). Thus, BCG vaccination alters the ensuing polyfunctional profile upon 
infection with virulent M. bovis, favoring early IFN-γ/TNF-α/IL-2 production by CD4+ Tcm’s 
and dampening TNF-α/IFN-γ elicited by infection. 
 
Figure 9. Kinetics of IFN-γ TNF-α IL-2 and IFN-γ TNF-α responses by Tcm.  
For long-term culture, PBMCs isolated at 6 weeks post vaccination (6 WPV), 3 weeks post 
infection (3 WPI) and 8 WPI were stimulated with a cocktail of Ag85A, TB10.4, and PPD 
for 13 days followed by transfer to 96 well round bottom plates with APCs and addition of 
media alone, Ag85A/TB10.4 or ESAT-6:CFP10 for an additional 16h. Results are 
presented as average and standard error. Percentages of long-term cultured Tcm’s (gated on 
CD45RO+/CCR7+/CD4+ cells) producing IFN-γ/TNF-α/IL-2 or IFN-γ/TNF-α upon recall 
stimulation with Ag85A/TB10.4 (A and B) or ESAT-6:CFP10 (C and D).  
* Differences (P < 0.05, Tukey’s) in the cytokine production by non-vaccinates and 
vaccinates. 
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Vaccination elicited protection is associated with reduced IFN-γ/TNF-α responses by Tcm’s 
early after challenge. 
After M. bovis challenge, Th-1 responses to mycobacterial antigens generally correlate with 
TB-associated pathology and poor vaccine efficacy 15, 53, 58,59. In our study, both vaccines 
provided a high level of protection. M. bovis was isolated from only five vaccinated animals (4 
BCG mutants and 1 BCG vaccinate). Retrospective analysis comparing responses to early 
infection (3 WPI) by non-vaccinates versus culture negative vaccinates (n=14) or culture 
positive vaccinates (n=5) revealed differential IFN-γ/TNF-α responses by Tcm’s to ESAT-
6:CFP10 among the groups (Fig. 10A, P < 0.05). IFN-γ/TNF-α responses by Tcm’s from non-
vaccinates were higher than that of both M. bovis culture negative and positive vaccinates (Fig. 
10A, P > 0.05). M. bovis culture positive vaccinates produced intermediate cytokine levels, 
while culture negative animals had the lowest IFN-γ/TNF-α responses (Fig. 10A, P < 0.05). 
Conversely, IFN-γ/TNF-α/IL-2 production by Tcm’s was higher in culture negative vaccinates 
as compared to culture positive non-vaccinates (Fig. 10B, P > 0.05). IFN-γ/TNF-α/IL-2 
responses by Tcm’s from culture positive vaccinates were intermediate; not differing from 
either culture negative vaccinates or non-vaccinates (Fig. 10B, P < 0.05). IFN-γ/TNF-α/IL-2 
and IFN-γ/TNF-α production by Tem’s in ex vivo assays did not differ among culture negative 
and culture positive animals (Fig. 10C and 10D, P > 0.05). Thus, these results indicate that 
strong IFN-γ/TNF-α responses by Tcm’s are associated with greater mycobacterial burden 
while IFN-γ/TNF-α/IL-2 responses by Tcm’s are indicative of a protective response provided 
by vaccination.  
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Figure 10. IFN-γ/TNF-α/IL-2 and IFN-γ/TNF-α polyfunctional reponses at 3 
weeks post infection by Tcm’s, but not by Tem’s, differ based upon M. bovis 
colonization and vaccination status. Calves were grouped accordingly with both 
vaccine status and bacterial burden results (culture positive or negative) for assessment 
of of IFN-γ/TNF-α/IL-2 and IFN-γ/TNF-α Tcm response at 3 WPI. Long-term culture 
consisted of PBMCs isolated at 3 WPI and stimulated with a cocktail of Ag85A, 
TB10.4, and PPD for 13 days followed by transfer to 96 well round bottom plates with 
APCs and addition of media alone or ESAT-6:CFP10 for an additional 16h. Results 
are presented as average and standard error. IFN-γ/TNF-α and IFN-γ/TNF-α/IL-2 
polyfunctional responses by Tcm’s (gated on CD45RO+/CCR7+/CD4+ cells) from 
vaccinates (either culture positive or negative) or non-vaccinates upon recall 
stimulation with ESAT-6:CFP10 (A and B). IFN-γ/TNF-α and IFN-γ/TNF-α/IL-2 
polyfunctional responses by Tem’s (gated on CD45RO+/CCR7-/CD4+ cells) vaccinates 
(either culture positive or negative) or non-vaccinates upon recall stimulation with 
ESAT-6:CFP10 (A and B). 
abc Different letters differences (P < 0.05, Tukey's) in cytokine production among 
vaccinates (culture positive and negative) and non-vaccinates.  
* Differences (P < 0.05, Tukey's) in the cytokine production between culture negative 
vaccinates and non-vaccinates. 
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Discussion 
TB in cattle shares many features with TB in humans and studies with neonatal calves are 
particularly pertinent to human TB as children are the primary target population for vaccination 
and exposure to TB often occurs at a very young age 1. Also, in contrast to laboratory mice, 
cattle are out-bred; thus, experimental variance is more similar to that of humans and of 
relevance for evaluation of safety and efficacy of vaccines, adjuvants, or other administered 
biologics. This can have significant advantages for a translational understanding of the 
mechanisms of pathogenesis and, more importantly, immunity. While correlates of vaccine-
induced protection against TB are not entirely understood, Tcm’s are presumed to be critical 
for protection in cattle and humans1, 13, 18, 20, 27, 30. Likewise, the role of polyfunctional CD4 T 
cells in the immune response to TB is not well established. Here we have shown that two 
protective BCG vaccine formulations elicited similar polyfunctional responses in vaccinated 
calves, and that early upon challenge with virulent M. bovis, responses by protected animals 
exhibited a different profile of response by Tcm’s as compared to that of unprotected animals. 
Protected vaccinates had a lower frequency of ESAT-6:CFP10-specific Tcm’s co-producing 
IFN-γ and TNF-α, suggesting that the incitement of strong Tcm IFN-γ/TNF-α responses early 
upon infection is related to a higher bacterial burden and inability of the host to control 
mycobacterial growth. On the other hand, higher frequencies of Tcm’s producing IFN-γ/TNF-
α/IL-2 early after infection were associated with vaccine elicited-protection and bacterial arrest 
by the host.  
Polyfunctional cytokine responses were detected upon antigenic stimulation of freshly 
isolated and long-term cultured PBMCs with no difference in the percentages of cytokine 
producing cells based on culture condition. Still, the phenotype of responding cells greatly 
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differed, with enriched numbers of responding Tcm’s in long-term cultured cells and Tem’s in 
ex vivo cultures. This finding is consistent with previous research evaluating the phenotype of 
antigen specific cytokine producing cells in long-term cultures in humans 8, 11, 12 and cattle 
(Maggioli et al. 2014). As previously detected in naturally-infected cattle, experimental 
infection elicited polyfunctional responses biased toward IFN-γ/TNF-α and IFN-γ/TNF-α/IL-2 
profiles 21. In response to vaccination, long-term cultured PBMC responses were generally 
higher than that of ex vivo stimulated PBMCs. Long-term culture has been used as a method to 
improve the sensitivity of TB diagnostic tests for humans 60, 61, so it is reasonable to speculate 
that long-term culture enriches low frequency antigen-specific cells, as with vaccination, 
consequently aiding in response detection.  
As early as 3 WPI, IFN-γ/TNF-α responses by both Tcm’s and Tem’s (i.e., in long-term 
cultured and ex vivo assays, respectively) from non-vaccinates exceeded that of vaccinates. 
Yet, whether detection of Tcm responses in in vitro cultures so early upon infection was a 
consequence of in vitro conditions or whether antigen-specific cells, or their progeny, 
maintained their true phenotype throughout the in vitro culture requires further investigation. 
Studies have shown that the antigen specificity of responding cells in ex vivo and cultured 
ELISPOT assays do not necessary correlate to each other with HIV 62 (Calarota et al. 2008), 
EBV 63, hepatitis C virus 11, or malaria infection 64, 65; demonstrating that the nature of the 
response by cytokine producing cells may differ based on culture conditions. Likewise, it could 
be argued that the stimulation protocol might have induced in vitro priming of naïve T cells. In 
vitro priming, however, is unlikely due to the relatively short duration of the assay, absence of 
peptide antigen stimulation during the initial 13 day culture phase, no addition of cytokines 
apart from IL-2, and no enrichment of dendritic cells - all of which are required for in vitro 
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priming 66. The absence of response to vaccine antigens by non-vaccinates prior to challenge 
further supports the notion that priming of naïve cells occurs in vivo, and not as a consequence 
of long-term culture. Moreover, IFN-γ responses to vaccination in long-term cultures are 
associated with protection upon M. bovis challenge, indicating that the assessed in vitro 
response does hold a connection to the in vivo outcome. 
Polyfunctional responses to ESAT-6:CFP10 (antigens not synthesized by BCG strains) 
were detected in effector, Tem and Tcm populations from BCG vaccinates early after 
challenge (3 WPI). This finding is consistent with the early asymmetric division model of 
maturation, indicating memory and effector T cells expand concomitantly during the effector 
phase of the response and relatively early upon infection 67-72. In the mouse model, BCG 
elicited Tcm’s are detected as early as 20 days after vaccination and correlate with improved T 
cell recruitment to the lung. Also, the adoptive transfer of Tcm’s, but not Tems, is sufficient to 
confer protection 5. Laouar et al. 68 demonstrated the appearance of CD8 memory cells during 
the acute phase of a primary response to lymphocytic choriomeningitis virus as early as eight 
days after infection. Likewise, prime-boost vaccination with viral-vectored vaccines expressing 
malarial antigens induce both ex vivo and cultured IFN-γ ELISPOT responses by seven days 
after boost 65. It is important to note that antigen clearance appears to have a crucial role on the 
kinetics of the response, and pathogen clearance in chronic infections such as TB (including M. 
bovis infection in calves), is not always achieved. Moreover, the very factors governing 
effector / memory T cell differentiation remain largely unknown. Whether memory cells arise 
(1) as direct progenies of effector cells (linear differentiation model; 73-75, (2) via a linear 
process dictated by a progressive loss of T cell differentiation potential (i.e., from naïve à 
effector à memory à terminally differentiated cells) dependent on antigenic stimulation and 
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signaling milieu (decreasing potential model; 76, 77, or (3) as a separate lineage from naïve cells 
(divergent differentiation model, 67, 69 has long been debated. Still, the connection between 
naïve CD4 T cells and the various effector and memory fates these cells follow remains 
elusive, and a single unifying theory accounting for the diversity of CD4 T cell memory has 
not been discovered 78, 79. This fact suggests that various mechanisms of CD4 T cell memory 
generation may be differentially engaged depending on various factors (e.g., level of 
inflammation), and that these models are not necessarily mutually exclusive. Still, cell fate 
divergence (i.e., asymmetric division) early after priming has been reported by several authors 
5, 65, 67-69, and is supported by the present findings, suggesting that memory generation begins 
prior to antigen clearance. 
Early upon infection, vaccinates exhibited higher numbers of antigen-specific IFN-
γ/TNF-α/IL-2 Tcm’s than did non-vaccinates, and such dissimilar responses between 
vaccinates and non-vaccinates early after challenge is associated with disease outcome. 
Polyfunctionality is often associated with less differentiated T cells (Tcm and Tem, as opposed 
to terminally differentiated T cells expressing killer cell lectin-like receptor 1 - KLRG1), and 
better quality of responses 27, 76, 79. Persistent or prolonged antigen stimulation is related to a 
progressive loss of the pool of long-lived central memory T cells, resulting in poorly fit 
immune responses by terminally differentiated, short-lived cells that produce single cytokine or 
loss of effector function all together 80, 27. The higher numbers of IFN-γ/TNF-α/IL-2 Tcm cells 
may indicate that vaccinated calves were able to control antigen load, retaining greater levels 
of cell functionality, which was beneficial in the long run. In future studies, we will evaluate 
KLRG1 expression on CD4 T cell effector / memory populations with the various 
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polyfunctional profiles over a longer course of M. bovis infection to determine KLRG1 
association with the expression of effector function by T cells in cattle.  
As both vaccine treatments were proven to be exceptionally protective, we investigated 
whether vaccinated animals with no detectable M. bovis by quantitative culture responded to 
infection differently than did vaccinated animals with detectable M. bovis and/or non-
vaccinates (all of which had detectable M. bovis by quantitative culture). Surprisingly, IFN-
γ/TNF-α responses by Tcm’s differed among all three groups, suggesting colonization, and 
perhaps antigen load, could be associated with the number of IFN-γ/TNF-α antigen-specific 
cells. Intriguingly, similar numbers of Tcm’s producing IFN-γ/TNF-α/IL-2 were detected in 
vaccinates, regardless of their culture status. Still, IFN-γ/TNF-α/IL-2 responses were greater in 
vaccinates as compared to non-vaccinates, indicating that vaccine-induced IFN-γ/TNF-α/IL-2 
responses may be associated with protection. Also, low levels of TB associated pathology was 
present in a few vaccinates with no detectable M. bovis by quantitative culture. It is known that 
few bacilli are required to cause TB associated pathology, and the vaccine may have reduced 
the bacterial burden below the limit of M. bovis detection. Interestingly, three vaccinates with 
detectable M. bovis by quantitative culture showed no TB associated pathology (lung and lung-
associated lymph nodes). It is possible that TB associated pathology was only delayed by 
vaccination and these animals would still progress to clinical disease. It also indicates that even 
though vaccinates with detectable M. bovis had higher numbers of Tcm producing IFN-γ/TNF-
α as compared to vaccinates with no M. bovis, the moderate levels of IFN-γ/TNF-α/IL-2 (or a 
combination of factors) would have conferred, if not a sterilizing protection, a significant 
decrease/delay in TB associated pathology even in the presence of the pathogenic bacilli. This 
scenario would still be beneficial to the host. 
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Tcm’s expressing IL-2 are associated with latent TB or effective anti-mycobacterial 
therapy in humans, whereas patients with active TB predominately exhibit effector cells that 
express IFN-γ/TNF-α 32, 81,82. This suggests that CD4 T cell functional capacity is driven 
toward terminally differentiated T cells by bacterial load and continuous antigen exposure 
32.While the occurrence of latency is not well established in cattle, non-vaccinates and non-
protected vaccinates exhibited higher IFN-γ/TNF-α responses by Tcm’s than did protected 
calves early after challenge, similar to what occurs with active disease in humans. 
Additionally, protected vaccinates exhibited higher numbers of IFN-γ/TNF-α/IL-2 producing 
Tcm’s. It is plausible that the amount of initial antigen exposure controls the extent of 
differentiation, and that vaccinated animals were more capable of containing the infection 
initially, preventing the loss of CD4 polyfunctional capacity. Moreover, single IL-2 producers 
did not differ among vaccinates and non-vaccinates or vary dependent upon M. bovis culture 
status at necropsy, which may indicate that the polyfunctional capacity, and not IL-2 
production per se, was the most relevant protective response assessed. Such responses could be 
either a surrogate of other protective mechanisms or a just an indication of immune response 
fitness (e.g., the presence of Tcm exhibiting plasticity, more prone to long-lasting, or 
producing other cytokines). Protection to TB may require different levels of Tcm and Tem 
memory responses and also different ratios of Tcm’s to Tem’s in the different phases of this 
chronic infection 83. It is also possible that the presence of Tcm’s producing IFN-γ/TNF-α/IL-2 
was a consequence of lower bacterial burden, rather than its cause. Importantly, Sakai et al. 84 
demonstrated in the mouse model that differentiated T cells expressing KLGR1 elicited by 
BCG-vaccination are retained within lung blood vasculature, lacking the ability to migrate into 
the lung parenchyma. Although these cells may produce high levels of IFN-γ, they are still 
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functionally impaired and unable to confer protection in the lung. Kaushal et al. 85 showed that 
aerosol immunization of macaques with an MtbΔsigH mutant was highly protective against an 
otherwise lethal M. tb aerosol challenge. MtbΔsigH vaccinated macaques exhibited higher 
numbers of Tcm’s in response to vaccination (as compared with BCG or non-vaccinated 
controls) and higher percentages of IFN-γ/TNF-α/IL-2 in their lungs after challenge. The 
assessment of T cell survival, senescence and peripheral migration markers [(e.g., B-cell 
lymphoma 2 protein (BCL-2), KLRG-1 and programmed cell death protein 1(PD-1)], local 
responses in the lungs, as well the measure of a broader panel of cytokines would further the 
understanding of our findings, but such analysis were not achievable in the present 
experiments. 
Predicting vaccine efficacy is difficult, in part due to the lack of consistent 
immunological correlates of protection, especially one that would be appropriate throughout 
the different stages of chronic infections. Effective responses are likely not static, with 
different subsets displaying a variety of functions and migration capabilities necessary for 
disease prevention, bacterial arrest and infection resolution. Recently Ziraldo et al. 83 proposed 
a computational model to explore Tem and Tcm responses to a variety of mycobacterial 
antigens, generating a tool to predict vaccine formulations that would provide protective ratios 
of memory cells with desirable functionalities. If this approach proves to be successful, it 
would offer further insights into protection correlates and vaccination strategies to accomplish 
protection. In the mean time, present findings indicate that IFN-γ/TNF-α and IFN-γ/TNF-α/IL-
2 responses by Tcm’s early after M. bovis infection in cattle are associated with detrimental 
and protective outcomes, respectively. 
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In summary, determining the T cell responses by measuring their functionality in 
combination with cell surface phenotype is likely to increase the fundamental understanding of 
T cell memory and effector differentiation, as these parameters define the T cell functional 
capacity, life-span potentials, antigen exposure history and trafficking capabilities. Thus, 
phenotypic and functional analysis of T cells offers an assessment of the quality of the immune 
response, allowing a clearer evaluation of whether and how a response is protective, than either 
of these parameters measurement alone. 
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Supplemental Information 
 
 
S1. Gating strategy for assessment of polyfunctional cytokine responses by 
effector/memory phenotypes in long-term and ex vivo culture conditions. A representative 
polyfunctional response from an infected animal is presented to demonstrate the gating 
strategy. (A) Selection of populations containing live CD4+ singlets within the lymphocyte gate 
(based on FSC and SSC properties). Each subsequent panel shows only the population of 
interest that has been selected from the gate on the previous plot. (B) CD4 cells producing IFN-
γ, IL-2 or TNF-α in response to PPD, followed by combinatory Boolean analysis for 
polyfunctional cytokine profiles. (C) CD4 T cells producing any cytokines of interest were 
then analyzed for CD45RO/CCR7 expression to further discriminate the polyfunctional CD4 T 
cell response by effector/memory phenotype in ex vivo (light blue) and long-term cultures 
(dark blue). (D) Expression of cell markers on different T cell memory/effector subsets. 
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S2 . Cytokine production by CD4 T cells under long-term or ex vivo culture conditions in 
response to vaccination. For long-term culture, PBMCs were isolated and stimulated with a 
cocktail of Ag85A, TB10.4, and PPD for 13 days followed by transfer to 96 well round bottom 
plates with APCs and addition of media alone or PPD for an additional 16h. For ex vivo 
cultures, PBMCs were isolated and stimulated with media alone or PPD (5 µg/ml) for 16h. 
Results are presented as average and standard error. Frequency of long-term and ex vivo 
cultured CD4 T cells producing IFN-γ (A), TNF-α (B), or IL-2 (C).  
abcDifferent letters represent differences (p < 0.05) in cytokine production in long-term and ex 
vivo culture conditions for each individual cytokine (ANOVA followed by Tukey's multiple 
comparisons test). 
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S3. Polyfunctional cytokine production to Ag85A/TB10.4 by PBMCs from BCG or BCG 
mutants under long-term or ex vivo cultures at 6 weeks post vaccination. For long-term 
culture, PBMCs were isolated and stimulated with a cocktail of Ag85A, TB10.4, and PPD for 
13 days followed by transfer to 96 well round bottom plates with APCs and addition of media 
alone or Ag85A/TB10.4 for an additional 16h. For ex vivo culture, PBMCs were stimulated 
with media alone or a cocktail of Ag85A/TB10.4 for 16h. Results are presented as average and 
standard error. Percentage of cytokine production profiles among memory subsets in response 
to recall stimulation of long-term cultures with Ag85A/TB10.4 by BCG-vaccinates (A) or 
BCG mutants-vaccinates (B). Percentage of the cytokine production profiles among memory 
subsets in response to ex vivo stimulation with Ag85A/TB10.4 by BCG-vaccinates  (C) or 
BCG mutants-vaccinates (D). 
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S4. Polyfunctional cytokine production to PPD by PBMCs from BCG mutants- or BCG-
vaccinates under long-term or ex vivo cultures at 6 weeks post vaccination. For long-term 
culture, PBMCs were isolated and stimulated with a cocktail of Ag85A, TB10.4, and PPD for 
13 days followed by transfer to 96 well round bottom plates with APCs and addition of media 
alone or PPD for an additional 16h. For ex vivo culture, PBMCs were stimulated with media 
alone or PPD for 16 h. Results are presented as average and standard error. Percentage of the 
cytokine production profiles among memory subsets in response to recall stimulation of long-
term cultures with PPD by BCG-vaccinates (A) or BCG mutants-vaccinates (B). Percentage of 
the cytokine production profiles among memory subsets in response to ex vivo stimulation with 
PPD by BCG-vaccinates (C) or BCG mutants-vaccinates (D). 
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S5. Polyfunctional cytokine production by PBMCs from BCG mutants or BCG 
vaccinates under long-term or ex vivo culture conditions. For long-term culture, PBMCs 
were isolated at 3 weeks post infection and stimulated with a cocktail of rAg85A, rTB10.4, and 
PPD for 13 days followed by transfer to 96 well round bottom plates with APCs and addition 
of media alone or ESAT-6:CFP10 for an additional 16h. For ex vivo culture, PBMCs were 
stimulated with media alone or ESAT-6:CFP10 for 16 h. Results are presented as average and 
standard error. Percentage of the cytokine production profiles among memory subsets in 
response to recall stimulation of long-term cultures with ESAT-6:CFP10 by BCG-vaccinates 
(A), BCG mutants-vaccinates (B) or non-vaccinates (C). Percentage of the cytokine production 
profiles among memory subsets in response to ex vivo stimulation with ESAT-6:CFP10 by 
BCG-vaccinates (D), BCG mutants-vaccinates (E) or non-vaccinates (F). 
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S6. Cytokine production elicited by M. bovis infection exceeded respective responses to 
vaccination. For long-term culture, PBMCs were isolated at 8 weeks post infection and 
stimulated with a cocktail of rAg85A, rTB10.4, and PPD for 13 days followed by transfer to 96 
well round bottom plates with APCs and addition of media alone or ESAT-6:CFP10 for an 
additional 16h. For ex vivo culture, PBMCs were stimulated with media alone or ESAT-
6:CFP10 for 16 h. Results are presented as average and standard error. Percentage of the cells 
exhibiting polyfunctional profile to vaccination (6 WPV) and infection (non-vaccinates; 
8WPI), in response to recall stimulation of long-term cultures with Ag85A/TB10.4 (A) or PPD 
(B). Percentage of the cells exhibiting polufunctional profile to vaccination (6 WPV) and 
infection (non-vaccinates; 8WPI), in response ex vivo recall stimulation with Ag85A/TB10.4 
(C) or PPD (D).  
* Differences (P < 0.05, Tukey's) in the cytokine production between by vaccinates (at 6WPV) 
and non-vaccinates at either 3 or 8 WPI (ANOVA followed by Tukey's multiple comparisons 
test). 
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CHAPTER 5: SUMMARY AND CONCLUSIONS 
 
The research included in this thesis had the objective to characterize the phenotype of 
memory cells and aspects of their functionality in cattle, specifically in response to bTB 
infection and vaccination. The first manuscript describes long-term culture of PBMCs as a tool 
to enrich Tcm cells in cattle and an IFN-γ ELISPOT for cytokine production evaluation. The 
second manuscript describes for the first time, fundamental characteristics of Tcm (enriched by 
long-term cultures) in the response to bTB in cattle, as compared to Tem and effector 
counterparts. Bovine Tcm cells, as for many species, have greater proliferative capabilities and 
highly express SLO homing molecules. The third manuscript furthers the knowledge in 
memory responses to BCG vaccination by measuring IL-2 or TNF-α along with IFN-γ 
production, and also their association with protection or disease progression. Polyfunctional 
Tcm producing IFN-γ/TNF-α were associated with M. bovis culture, and these responses were 
significantly higher with culture positive calves in comparison with that of culture negative 
calves. Lack of cultivable M. bovis was associated with increased percentage of Tcm cells 
producing IFN-γ/TNF-α/IL-2. This study (presented in the third paper) provides relevant 
insights into memory formation and possible influences of bacterial load in the memory 
response in the context of bTB, representing a significant advancement to the veterinary 
immunology field. The discrimination of cell phenotype involved in cytokine production under 
both cultured and ex vivo conditions have proven to be helpful in identifying specific correlates 
of vaccine efficacy, which is a useful for selection of vaccine candidates for costly efficacy 
trials in BSL-3 facilities. 
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In the last few years it has became clear that memory T cells are extremely 
heterogeneous and complex. While improvements have been achieved to identify different 
components of immunological memory, little has been successfully applied to produce more 
effective vaccines against HIV and TB, or therapeutic approaches to infectious diseases. Also, 
as the classification of effector/memory subsets become more complex, concerns are raised 
regarding past studies. The use of fewer (or different) markers has possibly led to the wrong 
classification of memory and effector cells and consequently to incomplete conclusions. Also, 
studies have systematically excluded assessment of memory responses in peripheral tissue 1-3, 
which may constitute a relevant source of protection, and understanding of how these cells are 
established, and how to manipulate their formation may be necessary to improve vaccines 
strategies. Future studies should focus on analyzing resident memory cells, and also expand the 
markers and cytokines analyzed in both circulating and resident T cells.  
Determining the T cell response by measuring their functionality in combination with 
cell surface phenotype expands the fundamental understanding of T cell memory and effector 
differentiation, by defining their functional capacity, life-span potential, antigen exposure 
history and trafficking characteristics. Thus, phenotypic and functional analysis of T cells 
offers an assessment of the quality of the immune response, allowing a clearer evaluation of 
how response are protective; than either of these measurements alone. Such knowledge is 
likely to yield more protective and safer vaccines, which would benefit livestock farmers, 
diminishing the socioeconomic impact of infectious diseases (including TB) to farm animals, 
while also improving food safety and reducing zoonotic transmissions to humans.  
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Several devastating human diseases and conditions (such as cancer, HIV, autoimmunity 
and organ transplantation rejections) remain relatively poorly treatable and not curable. 
Preventive and therapeutic immunization and cell treatments for such health problems are 
challenges to be overcome by immunologists in the years to come 4,5. 
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